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ABSTRACT
Background and Purpose
The primary aim of this study was to investigate the impact of LSVT®BIG, an
intensive, whole-body, amplitude-based exercise protocol for people with Parkinson’s
disease (PwPD), on functional mobility, quality of life, and markers of neuroplasticity.
A secondary aim was to evaluate correlations between neurobiological measures
(serum brain derived neurotrophic factor - sBDNF) and functional changes associated
with the intervention.
Methods
Nine people with Parkinson’s disease (PwPD), age = 69.9 years ± 4.9, were
recruited from the local community and enrolled in LSVT BIG, which includes 16,
one-hour individual treatment sessions delivered over one month (4 sessions per week
for 4 weeks). Dependent variables were measured at baseline (BASE), end of
treatment (EOT), and 4 weeks after EOT (EOT+4). Mobility measures included stride
length, gait speed, step length, functional gait assessment (FGA), MiniBEST Test,
Timed Up and Go (TUG), and the MDS-UPDRS Part III Motor. Psychometric selfreport measures of fatigue, depression, confidence with activities, and Parkinson’s
disease quality of life were also included. Cellular neuroplasticity was evaluated using
changes in sBDNF.
Results
Statistically significant (a = .05) changes were identified in four of the six
primary mobility variables at EOT+4 including the MDS-UPDRS Part III:

Motor Examination, Functional Gait Assessment (FGA), MiniBEST balance, and step
length but not in gait speed or the TUG. Participants made statistically significant
changes at EOT and EOT+4 on the Activities-specific Balance Confidence (ABC)
measure. No statistically significant changes were identified in measures of fatigue,
depression, or health related quality of life measures. The sBDNF levels showed a
10.11% decline at EOT and an overall 30.94% decline from BASE to EOT+4, which
was statistically significant but was weakly correlated with all mobility and
psychometric variables.
Discussion and Conclusions
LSVT BIG is an effective behavioral treatment intervention for PwPD that can
be implemented in a clinical setting for people experiencing mild to moderate disease
severity. Improved function on several mobility variables, confidence with activities,
and a positive impact on quality of life which was consistent with our first and second
hypothesis. The strength of LSVT BIG may lie in its utilization of principles of
neuroplasticity especially mode of delivery, saliency, intensity, frequency, and
duration. Future research into the role each of these components may play will help
guide future exercise prescription and open options for application of LSVT BIG to
people with other neurologic diagnoses and beyond the population of PwPD.
A decline in sBDNF levels was significant but in contrast to the expected
hypothesized increase in levels. There was an unexpected weak negative relationship
with sBDNF across several variables. This decrease versus increase may be
interpreted as a reflection of decreased disease load but requires further investigation

and integration of additional neurotrophic factors to further expand our understanding
of the role of sBDNF and its response to exercise.
This study provides insight into the potential benefits of a behavioral
intervention that incorporates principles of motor learning that drive activity
dependent changes in neural plasticity. Improvement in mobility measures were not
statistically significant immediately following treatment but were significant four
weeks following the completion of treatment. This finding may reflect that measurable
changes in behavior occurred prior to changes in neural plasticity that is consistent
with previous research (Adkins, Boychuk, Remple, & Kleim, 2006) and emphasizes
the need for long term follow up for PwPD to fully understand the impact of exercise
based treatment.
This study is unique in its integration of comprehensive functional,
psychometric, and neurobiological measures in PwPD to broaden our understanding of
the complex nature of exercise-induced neuroplasticity. These results further expand
the limited body of research in the area of PD behavioral interventions and markers of
neuroplasticity. In particular, this research has taken steps towards addressing the gap
in treatment research by identifying specific measures regarding the efficacy of LSVT
BIG, a well-defined treatment, as well as introduce the use of sBDNF as a potential
link between functional neuroplasticity and cellular neuroplasticity.

Keywords: Neuroplasticity; Parkinson’s disease: LSVT BIG; BDNF; Physical
Therapy
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CHAPTER 1

INTRODUCTION

This sickness has no boundaries
No oceans it won’t cross
An illness that’s invisible
Submerged in utter chaos
- Anonymous PwPD

Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting
the dopaminergic neurons of the substantia nigra pars compacta (SNpc) and affects
over one million people in the United States and up to three million people in all of
North America (Marras et al., 2018). People with PD (PwPD) experience a decline in
functional mobility and quality of life as well as an increased need for support due to
factors directly associated with the progression of motor and nonmotor symptoms.
Individuals diagnosed with PD continue to have limited options for treatment of
symptoms beyond pharmacological interventions such as dopamine replacement
therapy or surgery such as deep brain stimulation. People are often not referred for
physical therapy (PT), occupational therapy OT), or speech therapy (SLP) until there
has been significant disease progression and they demonstrate a marked decline in
quality of life, activities of daily living, impaired
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mobility, and/or speech or swallowing issues. Physical therapists address balance,
mobility, and gait issues for PwPD with a wide variety of behavioral (exercise-based)
treatment interventions. Research has revealed significant improvements with physical
functioning, health related quality of life (HRQoL), strength, balance, and gait speed
(Goodwin et al., 2008; Tomlinson et al., 2012) as a result of treatment but with limited
evidence to support which interventions are most effective for patients. A 2001
Cochrane review of Physiotherapy for Parkinson’s disease: a comparison of
techniques (Tomlinson et al., 2001) identified only seven potential randomized
exercise trials compared to 43 trials identified in 2012. This review identified research
supporting a variety of PT exercise interventions to be effective in PD but concluded
that there is no robust evidence to support any one physical therapy approach over
another in the treatment of PD related impairments (Tomlinson et. al., 2012). The
studies were subdivided into six categories because there was which included general
physical therapy, exercise, treadmill training, cueing, dance, and martial arts. The Lee
Silverman Voice Treatment (LSVT), specifically LSVTⓇBIG study (the focus of this
research), was one of those studies included (Tomlinson et al., 2012). This reflects the
growing interest in behavioral interventions for this population but more importantly,
the need to establish evidence-based treatment interventions and exercise prescription
recommendations within the PT discipline along with valid, sensitive outcome
measures.
In this study, we investigated the impact of LSVT BIG on functional mobility,
quality of life, and markers of neuroplasticity. Neuroplasticity is a general term used to
indicate the brain’s ability to reorganize itself in an adaptive manner in response to the
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environment or injury. For the purposes of this paper there will be two operational
definitions that will be utilized. The first is functional neuroplasticity which relates to
changes in the brain that are observed or measured as final neural activity or
behavioral response and represent the system-wide output. The second is cellular
neuroplasticity which represents the vast collection of brain changes that include
molecular, structural, and biological components. These include, but are not limited to,
increased dendritic spine density, changes in receptor density, angiogenesis,
neurotrophic factor release, and synaptogenesis.
LSVT BIG is an intensive, whole-body, amplitude-based training protocol for
individuals with PD. LSVT BIG incorporates principles of motor learning that drive
activity dependent changes in functional neuroplasticity outlined by Kleim and Jones
(2008), including intensity, repetition, task specificity, “use it or lose it,” and salience
of treatment exercises. LSVT BIG, like other exercise interventions, has limited
evidence-based research to support treatment efficacy at this time. The purpose of this
study was to assess the impact of treatment on mobility, HRQoL, and serum brain
derived neurotrophic factor (sBDNF) of patients following administration of the
LSVT BIG program.
Individuals with PD were recruited from the local community and, after
undergoing an initial screening to ensure they met inclusion criteria, were seen for a
full assessment that included specific functional, balance and gait measures, nonmotor symptom self-report measures such as fatigue and depression, and a blood
draw. They then completed the LSVT BIG treatment protocol, which was one hour per
day, four days per week for four weeks. They were seen for a full follow-up
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assessment immediately after completion of the program and one month later. Blood
samples were drawn at each assessment time point and sBDNF levels were measured.
This provided an opportunity to assess the potential link between functional
neuroplasticity (changes in functional outcome in response to a treatment intervention)
and cellular neuroplasticity (sBDNF).

Principle aims of this study:
Aim 1: Determine the effects of LSVT BIG on functional mobility measures as
well as quality of life measures in people with Parkinson’s disease (PwPD).
Hypothesis 1: Exercise intervention using LSVT BIG will produce positive
statistically significant changes in functional mobility outcome measures in PwPD.
Hypothesis 2: Exercise intervention using LSVT BIG will produce positive
statistically significant changes in psychometric measures including quality of life in
PwPD.
Aim 2: Determine the correlation between neurobiological measures (serum
BDNF) and functional changes associated with a behavior treatment intervention
(LSVT BIG).
Hypothesis 3: There will be measurable increases in sBDNF levels following
LSVT BIG treatment as a result of intensive exercise.
Hypothesis 4: There will be positive correlation between increased sBDNF
level and improvement in functional mobility outcomes measures.
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CHAPTER 2

REVIEW OF LITERATURE

Parkinson’s Disease Overview
Parkinson’s disease (PD) was first described as the “the shaking palsy” in
James Parkinson’s original essay published in 1817. His description of the symptoms
of PD as “involuntary tremulous motion, with lessened power, in parts not in action
and even when supported; with a propensity to bend the trunk forwards, and to pass
from a walking to a running pace; the senses and intellects being uninjured” remains
true today (Parkinson 1817, p. 1). However, the etiology of PD and treatment of the
symptoms of PD remain incompletely understood. Parkinson’s disease is a complex
progressive neurodegenerative disorder affecting the dopamine (DA) producing
neurons in the substantia nigra, part of the basal ganglia network. It is characterized by
changes in motor function, specifically primary motor signs such as tremor,
bradykinesia, rigidity, and postural instability (Kandel, Swartz, and Jessell, 2013, p.
991-992). Additional motor signs can include micrographia, hypophonia, difficulty
swallowing, drooling, freezing, mask-like expression, and unwanted accelerated
movements. There are also nonmotor symptoms such as constipation, nocturia,
impacted sleep pattern, orthostatic hypotension, depression, and dementia. These
symptoms vary in severity as the disease progresses and can have a significant
negative impact on functional mobility as well as quality of life.
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Parkinson’s disease is the second most common neurodegenerative disease
after Alzheimer’s disease. The Parkinson’s Disease Foundation estimates PD affects
almost one million Americans, sixty-thousand people are newly diagnosed each year,
and a financial impact including direct and indirect costs are estimated to be $52
billion annually in the United States alone (Parkinson’s Foundation, 2019). The
number of people affected world-wide is estimated to be 6.2 million (GBD, 2018) but
could be as high as 10 million due to under reporting. A systematic review of 47
studies from 1985 to 2010 reported the overall prevalence of PD across the globe
ranges from 113 to 873 per 100,000 with males having a significantly increased
prevalence 134 per 100,000 compared with females at 41 per 100,000 (Pringsheim,
Jette, Frolkis, & Steeves 2014).
Age is the greatest risk factor for developing PD (Collier, Kanaan, and
Kordower, 2011; Collier et al., 2017; Reeve, Simcox, and Turnbull, 2014). The current
U.S. population of adults 65 years and older is expected to increase from 56.1 million
in 2020 to 73.1 million in 2030, a 30 percent increase with continued growth to 95.4
million, a 53 percent increase, by 2050 (United States Census Bureau, 2016).
According to An Aging World: 2105 International Population Report (He, Goodkind,
and Kowal, 2016), 617.1 million people of the 7.3 billion people worldwide are aged
65 years and older with a projected increase of more than 60 percent in just 15 years,
by 2030, the equivalent of 12 percent of the total population. This is expected to
increase to 16.7 percent of total world population of 9.4 billion by 2050. These
numbers will be mirrored by significant increases in the number of people world-wide
that will struggle with the consequences of disease, especially neurodegenerative
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disease such as PD. The significant impact of PD on individuals and society,
especially an aging society, supports the ongoing investigation of not only the
underlying causes but also evidence-based treatment approaches and a move towards
finding a cure.

Pathophysiology of Parkinson’s Disease
Anatomy and Circuitry
Parkinson’s disease is a progressive neurodegenerative disease associated with
dysfunction of dopaminergic neurons located in the substantia nigra (SN), which is
part of a group of nuclei called the basal ganglia (Little and Brown, 2014; Rizzi and
Tan, 2017). The basal ganglia are responsible for processing sensorimotor information
for proper movement generation, selection, planning, and execution of locomotion and
all voluntary movement (Rizzi and Tan, 2017). Four principal loops (motor,
oculomotor, executive/associative, and emotion/motivation) have been identified that
integrate this complex information to allow specific behavioral outputs (Martin, 2012;
Kandel et al., 2013). The motor loop includes the striatum (caudate and putamen)
which is the major input structure for the basal ganglia receiving inputs from cortex,
thalamus, and brainstem. Information is further modified within the basal ganglia via
intrinsic circuitry that includes the Globus pallidus externus (GPe), SN pars compacta
(SNpc) and subthalamic nucleus (STN). The STN receives inputs from GPe, cortex,
thalamus, and brainstem and sends output to Globus pallidus internus (GPi), GPe, and
SN pars reticulata (SNpr). The GPi is one of the major output structures along with the
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(SNpr) that sends signals upstream to the thalamus and downstream to the pedunculopontine nucleus in the brainstem. (Figure 1: Basal Ganglia Anatomy)

This complex network of communication and circuitry can be summarized by
the rate model which includes three intrinsic pathways – Direct pathway, Indirect
pathway, and a Hyper-direct pathway - each traversing different nuclei, releasing
different neurotransmitters, and modifying the output signal in different ways (Rizzi
and Tan, 2017). The direct pathway (motor-permissive or GO pathway), as its name
implies, is the shortest path for excitation and facilitation of movement (striatum – GPi
– thalamus). When the cortex releases glutamate to stimulate the striatum, this directly
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inhibits the GPi. The GPi is also inhibitory in nature, so when the striatum directly
inhibits the GPi, the result is increased firing in the thalamus which increases activity
in the motor cortex thus increasing movement. The indirect pathway (motorsuppressive or NO GO pathway) takes a more circuitous route (striatum – GPe – STN
– GPi – thalamus). When the striatum releases GABA at the GPi, it also releases it at
the GPe. The GPe normally inhibits the STN but if the striatum has inhibited or
decreased the amount of inhibition of the GPe this allows the STN to be facilitated.
The STN is excitatory and stimulates the GPi. When the GPi is stimulated it releases
more GABA onto the thalamus thereby inhibiting thalamic activity which results in
decreased motor cortex activation. The hyper-direct pathway is direct facilitation of
the STN via direct cortical input and causes less movement. (Figure 2: Basal Ganglia
Circuitry)

9

Internal to this network is a neuromodulation circuit, specifically the SNpc, the
mediodorsal portion of the SN which projects heavily to the striatum. These projection
neurons are dopaminergic and the DA they release bind to two different receptors in
the striatum, D1 and D2 receptors. Dopamine released by SNpc bind to D1 receptors
that excite the direct pathway and increase thalamic activity resulting in more
movement. The dopamine also binds to D2 receptors that inhibit the indirect pathway
which results in increased thalamic activity and results in more movement. This
modulation allows for finer tuned control of movement. However, under pathological
conditions such as decreased dopaminergic input in the case of PD, there is less
available dopamine to bind to D1 and D2 receptors resulting in less excitation of the
direct pathway and less inhibition of the indirect pathway with an end result of
decreased thalamic activity and less movement. (Figure 3: Modulation Circuit –
Dopamine)
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The basal ganglia and its related networks are known to play a key role in
procedural learning and movement regulation, therefore, damage to this region can
result in different types of movement disorders depending on the nuclei and pathways
affected. Movement disorders arising from involvement of this network can range
from hyperkinetic (too much DA) such as Huntington’s Disease to hypokinetic (too
little DA) such as Parkinson’s disease with characteristics well summarized by Kandel
et al. (2013, p.991), as “ impaired initiation (akinesia), reduction in amplitude and
velocity of voluntary movement (bradykinesia), muscular rigidity (increased resistance
to passive displacement), and a 4-6 Hz tremor at rest and flexed posture”. These
clinical manifestations of altered movement represent the cardinal motor impairments
associated with PD and are a direct result of decreased availability of DA as described
in the previous section. Although much of the literature is focused on motor
impairment it is important to keep in mind that individuals with PD also experience
sensory deficits, specifically, an alteration in sensory input and its integration into
modulation of motor behavior which contribute significantly to decreased internal
monitoring of amplitude of movements effecting motor production across speech and
mobility domains (Mahler, Ramig, and Fox, 2015; Farley and Koshland, 2005).

Cellular Pathogenesis
Dysregulation of DA is a central player in the clinical presentation of PD but
the cause of neurodegeneration of the DA system is not well understood. Advances in
technologies for improved staining and tissue analysis along with mapping of the
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human genome and the explosion of genetic research has provided further insight into
this question.
In 1912 Friedrich Lewy described intraneuronal inclusions in the nucleus
basalis of Meynert and the dorsal motor nucleus of vagus in the brains of people with
PD at autopsy which were later confirmed to be present in the substantia nigra and
other areas of the brain effected by PD as well (Shults, 2006). These inclusions were
subsequently named Lewy Bodies (LB)(spherical) and Lewy neurites (LN)(thread-like
appearance). Maria Spillantini (1997) utilized a staining technique to identify asynuclein (a-syn) as one of the proteins in the Lewy Bodies. This, along with
advances in genetics which identified two missense autosomal-dominant mutations in
the a-synuclein gene in kindreds with early-onset familial PD one year earlier, opened
an entirely new area of study into the pathogenesis of PD (Goedert, Spillantini, and
Davies, 1998) and the identification and definition of PD as a synucleinopathy
(Postuma et al., 2015).
The protein a-syn is a small, hydrophilic, natively unfolded, 140-amino acid
that normally exists in many nerve cells of the human nervous system (Braak et al.,
2004); it is located in presynaptic terminals (Goedert, Spillantini, and Davies, 1998;
Shults, 2006). The function of normally occurring a-syn is not fully understood
however, it has been suggested to play a role in the activity-dependent modulation of
nigrostriatal DA transmission, be involved in long-term regulation and maintenance of
presynaptic terminals and be required for the genesis and localization of presynaptic
vesicles and modulation of neurotransmitter release (Shults, 2006). Misfolding of asyn and subsequent aggregations and its’ relationship to PD has been well elucidated
12

over recent years and appears to have a central role in the underlying pathology of PD
(Desplats et al., 2009). When the cell cannot keep up with the demand to clear the
misfolded a-syn it starts to aggregate forming fibrils (LN) or cytoplasmic inclusion
bodies (LB). The inability of the cell to clear the misfolded a-syn, and additional
alterations in gene expression involving proteins involved in the breakdown and
clearance of intracellular proteins, has implicated the proteasomal system in the
pathogenesis of PD (Shults, 2006). It has been suggested that this excessive amount of
misfolded a-syn contributes to high amounts of oxidative stress and mitochondrial
dysfunction contributing to cell death of the dopaminergic neurons (Rietdijk et al.,
2017). Current literature supports three potential pathways involving LB and LN that
lead to cell death – protein aggregation, impaired protein degradation, and
mitochondrial and oxidative stress possibly also involving inflammation (Shults,
2006).
Accumulation of aggregated a-syn has been shown to follow a highly
predictable pattern of progression, from the olfactory bulb and lower brain stem to
higher centers of the neocortex (Desplats et al., 2009; Rietdijk et al., 2017; Braak et
al., 2004). Braak et al. (2003) published their hypothesis that PD is caused by a
pathogen that enters the body via the nasal cavity and is eventually swallowed entering
the nervous system by the digestive tract and enteric nervous system. They went on to
identify six neuropathological stages of the disease that can be divided into presymptomatic (stages 1 and 2) and symptomatic phases (stages 3-6). Each stage in the
Braak et al. model is marked by distinctive inclusion bodies that present as either
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Lewy neurites (LN) or Lewy bodies (LB) which are unique to PD and not signs of
“healthy” aging.
One thing that all the models agree about is that there are substantial changes
in the nervous system by the time there are enough symptoms to clinically diagnose
PD. This is important because even people who seek treatment soon after diagnosis
(and most don’t) already have significant disease (Braak et al., 2004).

The Role of Genetics and Epigenetic Triggers
Two forms of PD have been identified, familial and sporadic. Familial, or
hereditary forms of PD are rare, accounting for only 10-15% of cases while sporadic
PD, also known as idiopathic, accounts for 80-85% of diagnosed cases (Little and
Brown, 2014). Sporadic PD occurs in the general population, has no germ line
mutations but may have genetic contributions, and typically occurs in older
individuals (>60 years). Familial PD occurs in only specific kindreds, is an inherited
germ line dominant or recessive mutation and typically has an early onset (<60 years).
Several epigenetic triggers have been associated with PD. Direct and indirect
exposure to industrial chemicals such as manganese and carbon monoxide and
pesticides such as agent orange and permethrin can lead to an accumulation within the
human body and lead to severe injury to a multitude of systems including the nervous
system and associated motor impairments that are parkinsonism but not necessarily
confirmed PD (Weiner, Shulman, and Lang, 2013; Kim, Kim, and Kumar, 2019). It
has also been well established that parkinsonism can be drug induced by medications
such as neuroleptics like Thorazine and Haldol, antidepressants such as amitriptyline
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and trazodone, and antihypertensives such as methyldopa and reserpine all of which
produce extrapyramidal dysfunction and are reversible states with removal of the
offending agent. These are just a few of the identified potential environment triggers
that have come to light in the past few decades with many yet to be identified.
Understanding these potential environmental contributors to PD-like symptoms are
important to be aware of and screened for when assessing individuals with PD.
Research into familial PD, although much rarer, has led to discoveries into the
genetic causes of inherited forms of PD and has provided significant insight into the
underlying pathophysiology of sporadic PD. Each protein coded for by mutated genes
(i.e. PARK-2, PINK1, and LRRK2) appears to play a role in the proteasomal pathway,
mitochondrial function, or oxidative stress management. It suggests that when a
dysfunction in that protein occurs through altered genetic expression it acts in a toxic
manner in the cell leading to cell dysfunction and ultimately death. Genome-wide
association studies (GWAs) have provided support for PD to be considered a
“complex genetic disorder” meaning that not just one abnormal gene but an array of
genes (perhaps as many as 10-40) each exert a very small effect align and triggers PD
(Williams-Gray and Worth 2016; Weiner, Shulman, and Lang, 2013, p. 28). This,
along with further identification of environmental triggers and the process that leads to
cell death in vulnerable neuronal populations can assist in guiding the direction of
future research, developing biomarkers and diagnostic techniques for early detection,
treatment interventions, and perhaps ultimately a cure for PD.
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Diagnosis and Treatment of Parkinson’s Disease
Diagnosis, Clinical Presentation, and Diagnostics
There is no definitive test or biomarker for the diagnosis of PD and therefore it
is often a diagnosis of elimination based on symptomology, behavioral observations,
history of the evolution of symptoms, the systematic ruling-out of other potential
causes of parkinsonism, and response to levodopa medication (Postuma et al., 2015).
A pathological diagnosis of PD is definitive only through postmortem histological
analysis of brain tissue which confirms the presence of Lewy body pathology (LP) in
the basal ganglia (Jankovic et al., 2008; Trail, Protas, and Lai, 2008, p. 15). The
progression of the disease is as nonlinear and unpredictable across the population as
the presenting symptoms. It is critical for the individual to undergo a thorough
neurological evaluation when a Parkinson diagnosis is suspected as there are several
differential diagnoses based on underlying pathology requiring different treatment
approaches. Parkinsonism can be classified as four types: Primary PD (idiopathic),
Secondary PD (acquired), Heredodegenerative (inherited), and multisystem
degeneration (Parkinson-Plus syndromes) (Jankovic et al., 2008). Primary and
Heredodegenerative PD are typically very similar and can only be differentiated by
age of onset and genetic testing. Secondary parkinsonism can be caused by stroke,
brain tumor, post-encephalitic virus, toxins, drug induced (prescriptive and illicit), and
certain metabolic conditions while progressive supranuclear palsy (PSP), multisystem
atrophy (MSA), and cortico-basal degeneration (CBD) fall under the Parkinson-Plus
syndromes. In addition, other conditions such as normal pressure hydrocephalus,
essential tremor, and Creutzfeldt-Jacob Disease also need to be ruled out.
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The four cardinal features of PD are often identified with the acronym TRAP:
Tremor, Rigidity, Akinesia (also known as bradykinesia), and Postural instability with
a possible positive diagnosis considered when an individual has any two of these four
symptoms. The United Kingdom Parkinson’s Disease Society Brain Bank and the
National Institute of Neurologic Disorders and Stroke (NINDS) both have clear
diagnostic criteria outlined but neither reliability nor validity of these criteria have
been established. One study that looked at 100 people clinically diagnosed with PD
revealed only a 76% pathological diagnosis on postmortem analysis (Jankovic et al.,
2008). Once the cardinal signs have been confirmed the next step is to exclude any
other cause of the parkinsonism. Even though it has been identified that there is no
confirmatory diagnostic test for PD, medical evaluation such as blood work, MRI,
and PET scans may be performed. Positron emission tomography (PET) using 18Fflurodopa can show reduced uptake in the striatum, especially the putamen in PD
patients. Single photon emission computerized tomography (SPECT) with dopamine
transporter ligands, beta-CIT and TORDAT, also called a DaT-Scan quantitatively
measures the level of dopamine in the basal ganglia with a deficiency indicative of
Parkinsonism. This test, however, cannot differentiate between the four types
(Jankovic et al. 2008; Weiner, Shulman, and Lang, 2013, p. 114).
Even once a clinical diagnosis of primary PD has been made, there are three
further subtypes that have been identified: 1) postural instability and gait disorder
predominant (PIGD); 2) tremor-dominant (TD), and 3) a mixed form (Jankovic 2008).
Postural instability and gait disorder predominant PD has been shown to present with a
poor prognosis and more rapid progression of the disease, a limited response to
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levodopa, and higher rates of depression and cognitive impairment when compared to
the Tremor-dominant type (Jankovic 2008).
PD severity scales are used to track the progression of the disease and to draw
a clearer clinical picture of the individual diagnosed with PD . The most universal is
the Unified Parkinson’s Disease Rating Scale (UPDRS) which was originally
developed in the 1980s. It was revised under sponsorship of the International
Parkinson and Movement Disorder Society (MDS) and renamed the MDS-UPDRS. It
is used as the primary international rating scale for PD clinical care and research
(Goetz et al., 2008). The MDS-UPDRS has four parts: I Non-motor Experiences of
Daily Living (13 items); II Motor Experiences of Daily Living (13 items); III Motor
Examination (18 items); IV Motor Complications (6 items). There is a 5-point range
for each item - normal (0), slight (1), mild (2), moderate (3), and severe (4) with a
higher score indicating higher disability. Factor structure of the new scale has been
determined to be both clinimetrically sound and clinically relevant when each of the
four parts (I-IV) are reported separately and not collapsed into a single “total MDSUPDRS” summary score (Goetz et al., 2008).
There has been a long history of interest in staging PD progression. In 1967
Hoehn and Yahr (H&Y) offered a staging schema with five categories which is still
used extensively today (Hoehn & Yahr 1967). These categories are: 0 –
Asymptomatic, 1 – Unilateral involvement only, 2 – Bilateral involvement without
impairment of balance, 3 – Mild to moderate involvement; some posture instability but
physically independent; Needs assistance to recover from the pull test, 4 – Severe
disability; still able to walk or stand unassisted, and 5 – Wheelchair bound or bed
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ridden unless aided. he Hoehn &Yahr scale mixes impairment and disability and is
considered nonlinear thus the MDS recommends it be used as a more global clinical
descriptor of disease severity such as demographic descriptor and for inclusion and
exclusion in research (Goetz et al., 2004).
The Braak staging, discussed earlier, is based on immunohistochemistry and
postmortem analysis and is not used as a clinical staging tool. Some studies support
the caudo-rostral development but identify a lack of correlation between medullary
and cortical disease severity (Kingsbury et al., 2010). Other studies indicate no
relationship between Braak staging and clinical severity of PD (Burke, Dauer, and
Vonsattel, 2008). This type of staging may play a different role in clinical
management in the future once a biomarker of early disease is discovered.
A clear understanding of disease severity and subtype can serve to clarify the
symptoms and their impact on mobility and quality of life as well as aid in decisions
regarding treatment options for PwPD.

Treatment Overview
Currently there is neither a cure for PD nor a disease modifying intervention
that will stop or reverse the progression of the disease (Kriebel-Gasparro, 2018)
although some progress has been made in disease deceleration in animal models
(Pedrosa and Timmerman 2013). Treatments available for people diagnosed with PD
are exclusively targeted at symptom management and fall into one of three categories:
pharmacological intervention; surgical intervention such as deep brain stimulation
(DBS); and behavioral intervention such as PT, OT, and ST (Pedrosa and Timmerman

19

2013). These interventions are based on clinical indicators as symptomatic
monotherapy, symptomatic adjunct therapy to levodopa, treatment of motor
complications such as dyskinesia, and prevention or delay of disease progression or
motor complications each with their own strengths and weaknesses (Fox et al., 2011).

Pharmacological Intervention
The current understanding of PD pathology points to the decreased DA
production as the primary perpetrator of the motor symptoms such as tremor and
rigidity. Therefore, pharmacological interventions to increase DA is considered to be
“best medical treatment” to address associated motor symptoms. Medications utilized
in the treatment of PD can replace DA or enhance existing DA levels and are usually
classified as 1) Carbidopa/Levodopa, 2) Dopamine agonists, 3) Anticholinergics, 4)
Monoamine oxidase inhibitor B (MAO-B), 5) Catechol-O-methyltransferase (COMT)
inhibitors, or 6) Other medications (Fox et al., 2018; Kriebel-Gasparro 2016).
One benefit of DA replacement therapy is clinically significant remediation,
and often elimination, of the specific motor impairments associated with PD such as
tremor, akinesia, and rigidity (Pedrosa and Timmerman 2013). These motor symptoms
are often the greatest complaint of people with the idiopathic PD and have the most
significant impact on their quality of life. They also report the most relief and easing
of symptoms once started on medication. There are drawbacks, however, to consider.
Most of the DA replacement medications have a very short half-life thus benefits are
short lived while high levels of DA in dorsal striatum (over time) allows increased
permissive signaling which can lead to dyskinesia and associated mental health issues
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such as obsessive-compulsive disorder and psychosis (Yahr et al., 1969).
Desensitization to medications requires higher doses and DA medications can become
ineffective later in disease process when they need it most, so the decision as to when
medications should start has been highly debated.

Surgical Intervention
In the early 1900’s surgical interventions for PD were primarily ablative
procedures targeting different regions of the basal ganglia. These were replaced by
medication due to the discovery of levodopa in the 1960’s. Surgery saw a resurgence
in the form of deep brain stimulation (DBS) in the 1980’s when in 1987 Dr. Alim
Benabid, a neurosurgeon from Grenoble, France, placed the stimulator in the ventral
intermediate nucleus of the thalamus as an effective treatment for tremor then later for
motor symptoms in PD. This led to FDA approval of DBS in 1997 for essential tremor
and 2002 for PD (Mirza et al., 2017; Hariz, 2017). Deep brain stimulation involves the
delivery of electrical impulses via an implant of electrodes deep in the brain with a
battery controller in the chest wall similar to a pacemaker (DeMaagd and Philip 2015).
The control unit allows for setting adjustments that can modulate the activity of deep
brain structures whose dysfunction is associated with common neurologic and
psychiatric conditions. The main target sites for DBS are the GPi and STN. The
Ventral Lateral posterior nucleus (VLp), an earlier target for ablative surgery, has been
found to be less comprehensive in addressing the cardinal symptoms using DBS when
compared with the STN or GPi and is therefore used only when other options are not
practical. The pedunculopontine nucleus (PPNa) has been considered an additional
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target that can provide management of freezing of gait (FOG) and gait disorders at low
frequencies (10-25 Hz) or potentially symptoms of postural instability at higher
frequencies (60-80 Hz) (Nosko 2015). These results, however, remain controversial
when compared to other studies. This suggests the need for further study, mapping of
circuitry, and development of more sophisticated stimulators and placement
techniques (Pedrosa and Timmerman 2013).
The GPi is a large anatomic structure and allows for more precise placement
and control of stimulation but because of this, it requires a much higher charge density
and more frequent battery replacement. In comparison, the much smaller STN is one
third the size and requires a lower amplitude pulse but can have more side effects
related to the spreading of signal to proximal limbic and associative loop pathways.
Thus consensus in the field supports an individualized and team decision based on
patient specific needs and symptoms as each site offers strengthens and drawbacks
based on therapeutic benefit, mechanism of action, and adverse effects and the overall
risk-benefit ratio (Mirza et al., 2017).
Treatment of PD symptoms using DBS has demonstrated significantly better
management of tremor and motor function and improved quality of life compared to
the best pharmacological intervention in PwPD. The recommendation from the
International PD and Movement Disorders Society regarding the use of DBS remains,
“efficacious for motor fluctuations and dyskinesias with the implication for clinical
practice as ‘clinically useful’ with ‘acceptable risk with specialized monitoring’
regarding safety concerns” (Fox et al., 2018, p. 1256). The main drawback is that DBS
has been associated with significant potential surgical complications including
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intracranial hemorrhage (4.4%), infection (4%), seizures (3.2%), and migration of
leads (2.4%) (Mirza et al., 2017) resulting in speech difficulties, balance issues, and
poor quality of life (Kahn et al., 2012; DeMaagd and Philip, 2015). According to
Mirza et al. (2017, p. 11) these “failures” can often be attributed to “inadequate
presurgical screening, improper patient selection, incorrectly placed leads, suboptimal
programming, battery failure, and hardware related issues” emphasizing the
importance of an interdisciplinary team approach to DBS treatment recommendations.
The use of DBS has allowed for the decreased use of medication by treating
the debilitating symptoms of Parkinson’s disease in more than 150,000 people
worldwide over the past 30 years. How DBS works, however, still has not been well
elucidated (Hariz, 2017; Mirza et al., 2017; Pedrosa and Timmerman 2013). It may
involve the modulation of thalamic signals and/or the local release of glutamate and
adenosine in the targeted areas (DeMaagd and Philip, 2015) or may have multiple
actions including a depolarizing blockade, synaptic inhibition, synaptic depression,
and stimulation-disruption of the pathological network (Pedrosa and Timmerman
2013). Ongoing research and future advances in technology will hopefully lead to
greater understanding of basal ganglia anatomy and circuitry allowing for greater
refinement of DBS targets and disease management in PD.

Behavioral Intervention
Pharmacological intervention focuses on amelioration of the cardinal motor
symptoms associated with PD but there is a broad range of additional motor and
nonmotor symptoms for which medications are not effective. Behavioral interventions
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such as exercise exert global and system wide changes throughout the nervous system
including release of neurotrophic factors, cardiovascular improvements, increased
mitochondrial energy production, and reductions in inflammation that can produce
further cascades of cellular neuroplasticity and neuroprotection not offered by
medication alone (Zigmond and Smeyne, 2014). Exercise should therefore be seen as
a primary or adjunct treatment for individuals with PD (Cotman, Berchtold, and
Christie, 2007).
Behavioral interventions provided by PT, OT, and SLP have been shown to be
highly effective in improving balance, gait, function, and quality of life especially as
an adjunct to pharmacological intervention (Tomlinson et al., 2012; Pedrosa and
Timmerman 2013) and have been recommended as “clinically useful” strategies (Fox
et al., 2018). The benefits are fairly extensive in that exercise and behavior
interventions have been shown to facilitate functional neuroplasticity (Voss, Erickson
et al., 2013; Montiero-Junior et al., 2015; Petzinger et al., 2013).
Clinical diagnosis based on manifestation of symptoms of PD often does not
occur until the SNpc has sustained at least 70 percent degeneration of the
dopaminergic neurons (Rizzi and Tan 2017). This aligns with the later stages outlined
by Braak’s model (2004) which indicates there are already significant and irreversible
changes in the nervous system by the time a PD diagnosis is determined. Early
diagnosis and referral for treatment is critical to potentially stave off functional
decline. Unfortunately, many patients are not referred to therapy until they are many
years into the disease process and significant functional impairments are beginning to
surface. Research still supports the benefits of exercise intervention even in later
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stages of the disease (Rafferty et al., 2017). The challenge can be that initiation and
motivation can be compromised (as part of the disease process) impacting an
individual’s ability and drive to participate in treatment and research.
The focus of PT intervention was initially based on a model that relied on the
relationship between the impairments in PD (the cardinal signs) and the subsequent
disabilities that resulted (Schenkman and Butler 1989). The earliest evolution of
physical therapy involvement in the individual with PD cited exercise as an important
regular part of their daily activities and that PT involvement should begin as early as
possible in the disease process (Schenkman and Butler 1989). Over the next few
decades scientific advances have been improving our understanding of PD pathology
and with it, evidence-based practice recommendations for PT and exercise prescription
have started to take a clearer form. Six core areas for PT to address in PD were
identified: transfers, posture, reaching and grasping, balance and falls, gait, and
physical capacity and activity (Kues et al., 2007). Comprehensive clinical summaries
(Ellis and Schenkman 2011, revised 2017) and an evidence based database (PD EDGE
2014) were developed by the American Physical Therapy Association (APTA) to
guide effectiveness. These resources also recommend clinical and research outcome
measures. Physical therapists are uniquely positioned as movement specialists to
address the needs of individuals with PD and work closely within an interdisciplinary
team to facilitate an optimal program with exercise and physical activity as a central
component.
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Role of Physical Activity and Exercise in the Treatment of Parkinson’s Disease
Along with diet/nutrition, sleep, and social interaction/mental stimulation,
exercise and physical activity are one of the cornerstones supporting a healthy lifestyle
for the general population. Exercise has the ability to stimulate tissue change and
adaptation such as increased muscle mass, strength, and cardiovascular endurance
(Johnston, 2018). This contributes to improved functional status related to sports,
activities of daily living (ADLs), and can protect against injury. The Centers for
Disease Control and Prevention (CDC) outline the many benefits of physical activity
including weight control, decreased risk of falls, cardiovascular disease, diabetes,
some cancers, pain management, strengthening of bones and muscles, improved
mental health and mood, improved ability to do ADLs, and increased longevity
(Center for Disease Control, 2018).
There is evidence in human and animal studies that suggest exercise-induced
brain plasticity occurs across the life span which may be interpreted to be
neuroprotective to age related health risks, such as the development of
neurodegenerative disease (Voss, Erickson, et al., 2013; Voss, Vivar, et al., 2013;
Zigmond and Smeyne 2014). Neurobiological hypotheses of physical exercise as a
treatment for PD include the hypothesis that physical exercise reduces chronic
oxidative stress, stimulates mitochondria biogenesis, and antioxidant enzymes become
more active and effective. A second hypothesis asserts that physical exercise
stimulates neurotransmitter (e.g. dopamine) and trophic factor (e.g. GDNF, BDNF)
synthesis thus providing maintenance of neuronal health and stimulation of
neuroplasticity (Montiero-Junior et al., 2015; Voss, Vivar, et al., 2013). Research into
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neurodegenerative diseases such as PD need to focus on interventions that will
facilitate neuroplasticity changes, provide neuroprotection, and/or prevent
neurodegeneration.
The 2008 Physical Activity Guideline (CDC, 2018) recommends that adults,
including adults with disabilities, get 150 minutes (2.5 hours) of moderate aerobic
activity or 75 minutes (1.5 hours) of vigorous activity per week. According to the
CDC, only 21 percent of adults and 27.8 percent of US adults 50 years or older with
disabilities met these guidelines (Oguh, Eisenstein, Kwasny, & Simuni, 2014). This
reflects a significant gap between research and actual practice yet also points to an
area of health behavior change that has significant promise and potential to improve
the lives of all adults in general, and PwPD specifically.
Studies have shown that physical activity improves movement initiation and
that higher patterns of lifetime physical activity were correlated with a lower incidence
of PD (Goodwin et al., 2008; Zigmond and Smeyne 2014). They also found improved
cortico-motor excitability in PD and increased cortical and hippocampal volumes in
the general population suggesting potential neuroplasticity and a potential role in
decreasing the risk of cognitive impairments. This suggests that midlife regular
exercise may reduce subsequent risk for PD as well as have a disease attenuating
effect (Ahlskog, 2011; Zigmond and Smeyne, 2014).
The research continues to support exercise interventions for persons newly
diagnosed with PD as well as those with more advanced disease. These
recommendations are slowly starting to be reflected in current clinical practice
(Speelman, van Mimwegen, Bloem, and Munneke, 2014; Oguh et al., 2014; Rafferty
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et al., 2017; Uhrbrand, Stenager, Pedersen, & Dalgas 2015). Organizations such as the
American Academy of Neurology (AAN) are acknowledging that while the past
treatment of PD focused on medications and surgeries with only a nod to exercise and
physical therapy, recent evidence suggests that exercise has multiple important health
benefits including improved physical and mental functioning and quality of life and
should be “recommended to ALL patients with PD” (Factor et al., 2016, p. 2281). The
National Parkinson Foundation recently published a longitudinal analysis of regular
exercise (>150 minutes per week), quality of life, and mobility in PwPD concluding
that exercising regularly was associated with small but significant protective effects on
quality of life and mobility over two years (Rafferty et al., 2017). There were greater
benefits of exercise in advanced PD suggesting that clinicians should encourage,
facilitate, and monitor long term exercise participation across all stages of PD
(Rafferty et. al., 2017). PwPD who exercise regularly (>150 minutes per week) were
associated with better quality of life, improved mobility and physical function, less
progression of disease, less caregiver burden, and less cognitive decline one year later
(Oguh et. al., 2014). Now that most agree that exercise is important as a treatment
intervention for PwPD, which exercise are the most effective?

LSVT BIG Treatment Intervention
The Lee Silverman Voice Treatment - LSVT®LOUD is an evidence-based
treatment intervention for speech disorders in PwPD supported with more than 25
years of treatment efficacy research. It is an intensive voice treatment for individuals
with PD that “requires intensive high effort exercise combined with a simple,
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redundant and salient treatment target to transfer loudness into functional daily life”
and “adheres to many of the fundamental principles of exercise and motor training that
have been shown to promote neural plasticity and brain reorganization in animal
models of PD” (Frazzitta et al., 2008, p. 257). The principles of LSVT LOUD were
applied to limb movement in PwPD and called LSVT®BIG. Initial results indicated
training large, axial body movements (large amplitude) resulted in improvements in
balance, posture, and distal functioning (Farley and Koshland, 2005). An LSVT BIG
study, often referred to as the Berlin study in the literature, compared this intervention
to a group Nordic walking program and a non-supervised home exercise program
(Ebersbach et al., 2010). The results indicated LSVT BIG participants made
significant improvement in their UPDRS scores as well as timed-up-and-go (TUG)
and timed-10 m test scores, supporting LSVT BIG as an effective technique to
improve motor performance in patients with PD.
LSVT BIG has been highly marketed making it a well-known treatment
available to PwPD but it has very limited research to support its efficacy and no
research supporting it as a significantly more effective treatment compared to other PT
interventions. A Cochrane Review of 43 studies revealed extensive research
supporting a variety of PT exercise interventions to be effective in PwPD but
concluded that there is no robust evidence to support any one physical therapy
approach over another in the treatment of PD (Tomlinson et. al., 2012). Ebersbach et
al. (2010) was the only BIG study included in that review.
Two separate review articles on evidence-based treatment interventions for
voice and speech in PwPD cite well over 20 studies supporting the efficacy of LSVT
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LOUD (Fox, Ebersbach, Ramig, and Sapir ,2012; Mahler, Ramig, and Fox, 2015) in
contrast, only two studies were cited in support of LSVT BIG (Ebersbach et al., 2010;
Farley and Koshland, 2005). A systematic review of LSVT BIG on the PubMed
database using the search parameters “LSVT BIG” and “Parkinson’s disease” by this
author performed 6/30/2018 and updated 7/12/19, identified only 13 articles after
duplicates, nonapplicable articles, posters, and reviews and commentaries were
removed. Six studies were excluded for the following reasons: Two were LSVT BIG
specific reviews (Fox et al. 2012; McDonnell et al., 2017); three were case studies
(Chatto, York, Slade, and Hansson 2018; Fishel, Hitchkiss, and Brown, 2018;
Janssens, Malfroid, Nyffeler, Bohlhalter,a nd Vanbellingen, 2014); and one was a
single subject design n=2 completed with individuals with stroke (Metcalfe, Egan,
Sauve-Schenk, 2019). The remaining seven articles included three prospective studies
(Farley & Koshland, 2005; Millage, Visey, Finkelstein, and Anheluk, 2017; Ueno et
al., 2017) and four randomized controlled studies (Dashtipour et al., 2015; Ebersbach
et al., 2010; Ebersbach, 2014; Ebersbach et al., 2015) of which three were by the same
author and two used data from the same study.
The Berlin study, is cited in support of LSVT BIG (Ebersbach et al., 2010) as
improving UPDRS motor, Timed Up and Go (TUG), and 10- meter walk test scores
compared to Nordic walking and home exercise programs. However, this study had
several significant limitations that impact the interpretation of the data. It had no
control group, either to neurotypical individuals completing the same intervention or
PwPD not completing any intervention. It looked at only motor outcome measures and
no quality of life or nonmotor symptoms. It compared three different treatment
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delivery systems - intensive one to one interaction (BIG), a group intervention
(WALK), and unsupervised exercise (HOME). It delivered those treatment
interventions at different intensities (BIG 4x a week x 4 weeks; WALK was 2x a week
x 8 weeks; HOME received a one hour instruction). They also did not look at
immediate outcomes but long term/residual effect at week 16 (BIG ends at 4 weeks
while the WALK group ended at 8 weeks).
The 2014 Ebersbach article re-utilized data from the original 2010 LSVT BIG
Berlin study and discussed the impact of BIG vs WALK vs HOME on cued and noncued upper extremity reaction. The results indicated that physical exercise in the BIG
and WALK groups was associated with improvement in cognitive aspects of
movement preparation expressed as improvements in cued reaction time in both
groups but not in the HOME group. There were no differences in non-cued reaction
time. A subsequent short protocol of BIG (5x a week 2 weeks) by the same researcher
found no difference in motor scores between the standard 4-week vs 2-week short
protocol but instead only revealed a difference in patient perceived benefit from the
treatment (Ebersbach et al. 2015).
Dashtipour et al. (2015) endeavored to address some of the limitations in the
Ebersbach et al. (2010) study. Their study which examined both motor and nonmotor
symptoms, compared LSVT BIG to a standardized exercise program delivered at an
equal intensity (1 hour), duration (4x a week x 4 weeks), and system of delivery (1:1
therapist). The study also assessed participants at baseline and immediately following
the intervention as well as at a 3 month and 6 month follow-up time point. They
concluded there was no difference between standard versus LSVT BIG intervention
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and that both were equally effective in improving motor symptoms as measured by
UPDRS, and that both interventions were associated with long term benefits at the six
month assessment. Their limitations included a small sample size (11 participants
(exercise n=5; LSVT BIG n=6) and all participants were in the early stage of the
disease. There continues to be a need for larger studies, with participants across the
spectrum of disease progression, and more comparative therapeutic treatment arms.
There is significant data in animal models of PD about the positive impact of
exercise on disease progression, however future studies are needed to assess the
impact of physical exercise on human PD progression (Hirsch et al., 2016; Voss,
Vivar et al., 2013). The authors of the chapter, Voice and Speech Disorders in
Parkinson’s Disease and Their Treatment (Fox et al., 2008) recommend future
research in LSVT LOUD needs to include documentation of long-term maintenance
effects, large multi-site effectiveness studies (clinical trials), alternative modes of
administration (e.g. different dosage intensity), and further study of treated PwPD to
better define predictors of success or failure with the treatment. These
recommendations can be applied to the study of LSVT®BIG as well. Further studies
are needed to understand the effectiveness of specific exercise interventions, ideal
exercise dosing, the impact on functional mobility and quality of life, and to support
consistent use of specific outcome measures and their validity. The current research
will contribute and further expand the growing body of research in the area of PD
behavioral interventions. This study includes the use of participants as their own
“control”, include an additional immediate completion time point to collect data as
well as an 8 week assessment, include more nonmotor symptom assessments, and
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integrate neurobiological measures in the form of BDNF serum levels. Additionally,
this study positions the next subsequent systematic study to start to examine changes
in dosage on outcome. In particular, this research takes steps towards addressing the
gap in effectiveness research by providing specific motor, non-motor, and
neurobiological measures regarding the efficacy of LSVT BIG, a popular and
mainstream intervention, despite limited research.

Neuroplasticity and Exercise Prescription
Prescription for PwPD
Physical activity is any bodily movement produced by skeletal muscle that
increases energy consumption and includes non-exercise activity and exercise
thermogenesis (Caspersen, Powell, & Christenson 1985; Voss, Vivar et al., 2013).
Caspersen et al. (1985) defines exercise as a subset of physical activity that is planned,
structured and repetitive and performed for the maintenance and improvement of
physical fitness. The neuroscience of exercise has been robustly explored at a
behavioral and cellular level in animal models but, due to obvious limitations of
obtaining human brain tissue samples, has favored more behavioral and assessment of
system-level changes for human models. Despite these limitations the findings in the
human research has been consistent with the rodent literature suggesting there are
broad and long-lasting benefits of exercise on brain function and structure (Voss,
Vivar et al., 2013). The search for human neurobiological measures has led
researchers to study the role of neurotrophic factors (NTFs) such as brain-derived
neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), insulin-like
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growth factor (IGF-1), and vascular endothelial growth factor (VEGF). Due to a
robust response to exercise-induced changes these NTFs may represent potential
biomarkers. Since BDNF and GDNF have been recognized as key proteins modulating
brain plasticity and are widely distributed throughout the brain (Ahlskog, 2011) they
may serve as a viable measure of brain health and neuroplasticity.
BDNF is a neurotrophin and a member of a family of proteins that is
responsible for the survival, development, and function of neurons and synaptic
plasticity and may be a viable biomarker for age and clinically relevant brain
dysfunction (Voss, Erickson et al., 2013). Although the underlying mechanisms of the
effect of exercise on cellular neuroplasticity is unclear, it is the neurotrophin that has
been proposed to mediate the effect (Voss, Vivar et al., 2013; Voss, Erickson et al.,
2013). A study by Voss, Erickson et al., (2013) evaluated the impact of a one-year
moderate aerobic exercise program on circulating BDNF, IGF-1, and VEGF levels in
healthy adults who had low baseline activity. Functional MRI studies to measure
changes in functional coupling (synaptic connectivity) were also conducted. They
concluded their results revealed the first evidence for an association between
circulating BDNF, IGF-1, and VEGF and exercise related functional plasticity in
humans. Exercise associated upregulation of NTFs may help offset age related
reductions in cellular neuroplasticity (such as synaptogenesis, angiogenesis, and
synaptic plasticity). This could lead to a more resilient brain in the face of age-related
structural and functional degeneration. Further research is warranted to further
understand how exercise type, duration, intensity can influence both functional and
cellular neuroplasticity.
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Understanding the mechanisms of neuroplasticity allows PT, OT, and SLP to
choose effective therapeutic interventions when treating individuals with neurologic
impairments. Kleim and Jones (2008) outlined ten principles of experience-dependent
neural plasticity and implications for rehabilitation following brain damage including
loss of function related to neurodegenerative disease. The first two are “use it or lose
it” and “use it and improve it”. These are fairly familiar concepts in that neural circuits
not activated over a period of time will start to degrade through the loss of neural
connections. Conversely, neural circuits that are stimulated will strengthen. These are
the underlying foundational principles employed in deprivation vs enrichment
research. Enriched environments have been linked to dendritic arborization, synapse
formation, neurogenesis, increased NTFs such as BDNF as well as an array of
molecules that promote N-Methyl-D-Aspartate (NMDA) function and facilitate long
term potentiation (LTP) (Griesbach and Hovda, 2015). In the case of PD, decreased
initiation (a component of the disease process itself) of an activity such as walking or
speech results in performing the task less frequently which contributes to a further
decline in function and loss of connectivity serving as a negative feedback loop.
Maintaining existing function and utilizing these existing circuits to expand further
functionality is a core tenant guiding rehabilitation interventions based on principles of
functional neuroplasticity facilitating return of function and/or prevention of loss in
function.
There is nothing more powerful in the toolbox of therapists trying to enhance
neuroplasticity than exercise! Exercise increases mitochondrial energy production,
stimulates antioxidant defenses, reduces inflammation contributing to improved
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immune function (Petersen and Pedersen ,2005), facilitates angiogenesis (Voss, Vivar
et al., 2013), produces synaptogenesis (Zigmond and Smeyne, 2014; Voss, Erickson et
al. 2013), and increases endogenous neurotrophic factors especially BDNF and GDNF
(Kleim and Jones, 2008; Hirsch, Iyer, and Sanjak 2016; Petzinger et al. 2013;
Monteiro-Junior et al. 2015; Cotman, Berchtold, & Christie 2007). All examples of
neuroprotection. Exercise can be seen as neurorestorative as it down regulates striatal
dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) thus
increasing dopamine in the extracellular space (Hirsch et al., 2016) which may help
restore neurophysiological properties of synapses within the injured striatum
(Petzinger et al., 2013). This is particularly important in the case of PD. Exercise may
also facilitate neuroplasticity and general brain health through its neuroprotective
mechanisms of increased cerebral blood flow which influences improved vasculature
through angiogenesis and altered blood brain barrier (BBB) permeability (Petzinger et
al., 2013; Voss, Vivar et al., 2013; Cotman et al., 2007). Further hypotheses are being
explored regarding the role of exercise in modifying genes and molecular pathways
and reversing dendritic spine loss further enhancing neuroplasticity at both a
neuroprotective and neurorestorative level. Integrating our understanding of
neuroplasticity can guide the timing, intensity, and frequency of exercise for optimal
outcomes.
The principles of functional neuroplasticity that most guide exercise
prescription are “specificity” (the nature of the training experience dictates the nature
of the plasticity), “repetition matters” (induction of plasticity requires sufficient
repetition), “intensity matters” (induction of plasticity requires sufficient training
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intensity), and “saliency matters” (the training experience must be sufficiently salient
to induce plasticity) (Kleim and Jones, 2008). Therapists must establish exercise
programs that are specific, integrate high repetition, high intensity, and have meaning
to the individual being treated whether the activity is movement or speech related.
Research is ongoing to find the “ideal” exercise prescription. Protocols such as LSVT
BIG and LSVT LOUD integrate these neuroplasticity principles effectively in the
treatment of individuals with Parkinson’s disease yet continue to try to balance
standardized protocol with patient-specific and individually designed (Farley, Ramig,
and McFarland, 2008; Ebersbach et al., 2010).
Exercise includes a wide variety of categories (stretching and flexibility,
aerobic capacity/endurance, strengthening, balance, and whole body such as martial
arts/dance), intensities (high versus low), and delivery modes (individual 1:1, group,
and independent). All of these variables that can impact treatment outcomes and make
it challenging to compare treatment interventions. While many studies support
exercise as a beneficial nonpharmacological intervention for people with PD
(Uhrbrand et al., 2015; King et al., 2015; Ridgel, Vitek, & Alberts, 2009; Schenkman
et al., 2012), a Cochrane Review from 2012 found formal comparisons and metaanalyses between exercise interventions specifically with PwPD was not possible due
to the extensive variability in implementation and clinical assessment, as well as
inconsistent descriptions of treatment regimens (Tomlinson et al., 2012).
Recommendations regarding exercise prescription including type, frequency, duration,
and outcome measures remain limited as a result of the diversity and inconsistency
within the literature.
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Conclusion
Parkinson’s disease is a progressive, neurodegenerative disease that has
significant detrimental impact on functional mobility and HRQoL as well as far
reaching emotional and financial consequences on individuals and caregivers living
with PD and society at large. Behavioral interventions, such as those delivered by PT,
OT, SLP can provide symptomatic relief and improve mobility and quality of life.
Despite a large body of evidence supporting exercise interventions as beneficial, this
study represents the research needed to specifically assess the efficacy of LSVT BIG
in PwPD and further elucidate the role these interventions may have on the functional
outcome and cellular substrates of neuroplasticity.
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CHAPTER 3

METHODOLOGY

Study Design
This study is a clinical effectiveness trial using a within-subject multiple baseline
design (MBD)(Montero and Le, 2007). Participants who met the inclusion criteria
received baseline assessments (BASE) including the MDS-Unified Parkinson Disease
Rating Scale, gait analysis, balance testing, quality of life surveys, depression survey,
fatigue survey, and physical activity assessment, as well as basic vitals and blood draw
to measure potential biomarkers of plasticity, such as brain-derived neurotrophic
factors (BDNF). Participants completed the LSVT BIG protocol, four one-hour
sessions per week for four weeks immediately following the BASE assessment.
Participants were instructed to continue performing their BIG exercises once daily for
the remainder of the study. Post-treatment assessments were performed the week
following end of treatment (EOT) and then a final follow-up assessment was
completed one month after the end of treatment (EOT+4). (Figure 4: Treatment
Protocol Timeline and Appendix A)
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Recruitment/Participants
Nine individuals with PD from the local community and ongoing programs at
the University of Rhode Island were recruited to participate in this study. A sample
size of eight was needed for determining statistically significant differences in the
dependent variables based on an a priori G-power analysis using a large effect of .8
and power of .80 (Faul, Erdfelder, Lang, and Buchner, 2007). Inclusion criteria
include diagnosis of idiopathic PD and no contraindications to exercise including
uncontrolled cardiovascular disease as well as sufficient cognition to complete the
exercises independently as part of homework. Comorbidities were documented as well
as disease severity. Exclusion criteria included history of stroke or other neurologic
diagnosis, or surgical procedure for treatment of PD including deep brain stimulator
(DBS), pallidotomy, or thalamotomy. Exclusion factors for the study were minimal so
as to include a broad cross section of people with PD (PwPD) in the study and more
closely resemble the variability seen in the clinical setting. Signed consent was
obtained from all participants for treatment and blood draws (Appendix B and
Appendix C).
The average age of participants was 69.9 years (± 4.9) with fairly even
distribution between gender 5/4 (male/female). The mean disease duration was 7.22
years (± 6) however there was a wide range from 1 to 17 years. A high number of
participants (n=7; 78%) reported experiencing On/Off periods related to their
medication. Participants were identified as tremor dominant (TD; 33%), postural
instability gait dominant (PIGD; 56%), or indeterminate (11%) based on their
UPDRS-III (Stebbins et al., 2013). There were no significant baseline differences
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noted between participants when checked for normal distribution except for H&Y
staging (p<.05) with 78% (n=7) stage 2 while 22% (n=2) were stage 3. (Table 1:
Demographic Characteristics)

LSVT BIG Intervention
The treatment protocol for LSVT BIG includes a total of 16, one-hour
individual treatment sessions delivered over one month (4 sessions per week x 4
weeks). Each session includes daily exercises, daily functional tasks, hierarchical
tasks, and carry over/homework (see Appendix D or Fox et al., 2012 for full protocol
description). The intervention was delivered by the lead PI and two students in the
physical therapy clinical doctorate program; all were certified in LSVT BIG. The
students were under the direct supervision of the lead PI and completed sufficient
treatment practice with non-research patients to the satisfaction of the principal
investigator, prior to assisting in research level treatment.
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Initial Assessment Measures
Comprehensive demographic and pertinent patient history/information was
collected during the initial interview including sex, age, race, education level, living
situation, current medications to allow for determination of levodopa equivalent daily
dosage (LEDD), disease severity (Hoehn & Yahr stage), PD subtype designation
based on MDS-UPDRS, and length of disease based on medical diagnosis. Additional
measures at baseline included the Cumulative Illness Rating Scale for Geriatrics
(CIRS-G) an interview-based instrument to measure medical comorbidity in
relationship to disability and has been validated for use with PwPD (Visser et al.,
2004); Next, the Montreal Cognitive Assessment (MoCA), a 30-point test, served as a
descriptive measure for cognitive status (Nasreddine et al., 2005). This test has been
used in a variety of patient populations and assesses eight cognitive domains: 1)
visuospatial/executive functioning; 2) memory and delayed recall; 3) attention; 4)
concentration; 5) working memory; 6) language and naming; 7) abstraction, and 8)
orientation. The MOCA provides a recommended cutoff score (<26) to detect mild
cognitive impairment (MCI) for people with PD. Specificity of the MoCA to exclude
elderly normal controls is good (87%) and sensitivity in detecting mild cognitive
impairment is excellent (90%) (Brown et al., 2016; Zadikoff et al., 2008); and, finally,
the Physical Activity and Disability Survey (PADS-R), a measure of physical activity
in people with neurologic conditions (Kayes et al., 2009). These measures are all
interview based questionnaires or tests that allowed for a clearer clinical picture of
each participant in accounting for medical comorbidities, cognitive status, and
physical activity levels, respectively. (Table 2: Clinical Characteristics)
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Objective measures of mobility in the off-medication state are more indicative
of patient perception of mobility disability and balance confidence compared with onmedication state measures (Curtze, Carlson-Kuhta, Mancini, and Horak, 2016)
however, review of the literature reveals the on-medication state is the state in which
most assessments are conducted and was the standard for this study.

Clinical Outcome Measures
Attempts to compare research on exercise and PD have been difficult due to
the inconsistency of outcome measures across studies (Tomlinson et al., 2012) and
lack of sensitivity of measures (King et al., 2013). The APTA Parkinson’s Disease
EDGE (Evidence Database to Guide Effectiveness) task force reviewed 60 outcome
measures, evaluated them for psychometrics and clinical utility, and formulated
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recommendations for which outcome measures that were highly recommended for use
in PwPD in the clinic as well as use for research (Kegelmeyer et al., 2014)., The task
force also took the three International Classification of Function, Disability, and
Health (ICF) identified levels (participation, activity, and body structure and function)
in their final recommendations.
The World Health Organization outlined the ICF in 2000 to integrate a more
comprehensive perspective of disability, complement research outcome measures, and
provide consistent, comparable, and universal guidance between researchers as well as
on an international level (Organization, 2000). The ICF interactive model identifies
three levels of human functioning: functioning at the level of body or body part, the
whole person, and the whole person in his or her complete environment. These levels
in turn define three functional dimensions: body functions and structures, activities,
and participation that can be addressed with specific measures. The outcome measures
utilized for this study were based on the ICF structure and APTA - PD EDGE
recommendations but for the purposes of this paper, are divided into mobility and
psychometric measures. (see Appendix D and E)

Functional Mobility Measures
The primary dependent variables, related to mobility, for the study were the
MDS-UPDRS Part III: Motor Examination, Functional Gait Assessment (FGA),
MiniBEST, gait speed, step length and TUG.
The Movement Disorder Society Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS; a revision of the UPDRS) is used as the primary international rating
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scale for PD clinical care and research (Goetz et al., 2008). The MDS-UPDRS has
four parts: I Non-motor Experiences of Daily Living (13 items); II Motor Experiences
of Daily Living (13 items); III Motor Examination (18 items); IV Motor
Complications (6 items). There is a 5-point range for each item - normal (0), slight (1),
mild (2), moderate (3), and severe (4) with a higher score indicating higher disability.
It is typically administered by a physician or allied health care professional that has
completed a training course. Confirmatory factor analysis of the new scale has been
determined to be clinimetrically sound (>.90) and clinically pertinent when reporting
results from each of the four sections. It has been recommended that each of the four
parts (I-IV) be reported separately and not collapsed into a single “total MDSUPDRS” summary score (Goetz et al., 2008).
The MDS-UPDRS Part III is comprised of 18 items but due to several
subsections has a total of 33 scores. Each item is scored with a 0-4 rating for a total
range from 0 to 136 with a higher score indicating higher level of severity and
disability. It also includes a question regarding medication, ON/OFF state at time of
exam, and a final Hoehn & Yahr stage rating (Goetz et al., 2008).
Functional mobility tests were performed to capture baseline and changes in
balance and gait measures and reflect tests that are accessible and feasible in a clinic
setting. The FGA is a 10-item test focused on a variety of gait tasks with each item
scored on a 4 point ordinal scale, 0-3 with a total score of 30. The higher the score the
higher the functional performance (Weber et al., 2016). The Mini-Balance Evaluation
System Test (Mini BESTest) is a clinical balance scale to assess falls risk and postural
control in people with PD with high test – retest reliability (ICC = .92) and inter-rater
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reliability (ICC = .91) (Duncan & Leddy 2013; Leddy, Crowner, and Earhart, 2011).
It is a 14 point unidimensional test modified from the original 36 item BESTest and
focuses specifically on dynamic balance (Bravini et al., 2016). Each of the 14 items
are scored on a 3-point ordinal scale (0-2 rating) with a maximum score of 28 and a
higher score indicating better performance (Franchignoni and Velozo, 2010;
Schlenstedt et al., 2015). It includes the TUG, an assessment of mobility, balance,
walking ability, and falls risk in older adults which has good inter-rater reliability
(ICC = .99) and intra-rater reliability (ICC = .98) and is useful for following clinical
change over time as well as predict safety with gait (Morris et al., 2001; Bennie et al.,
2003; Podsiadlo and Richardson, 1991). Finally, gait speed and step length were
determined using the 10-Meter walk, which, along with turning speed, have been
found to be highly negatively correlated to severity of disease and patient perception
of mobility disability (Curtze et al., 2016). (Refer to Appendix E)

Psychometric Measures
The ability of an individual to participate in day to day activities may be
restricted by functional mobility, however, they may also be limited by a variety of
psychological states such as an individual’s confidence in their mobility, fatigue level,
and mood which can ultimately have a considerable impact on their quality of life.
These states might influence an individual’s ability to benefit from or might change in
response to the treatment intervention therefore psychometrics were obtained at each
of the three assessment timepoints using a variety of self-reported measures.
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Confidence with mobility was measured using the Activities Specific Balance
Confidence Scale (ABC), a subjective self-reported measure of confidence in
performing various ambulatory activities without falling or experiencing a sense of
unsteadiness (Powell and Meyers, 1995). It is a 16-item questionnaire reported as a
percentage with 100% presenting the highest confidence. It has a high level of internal
consistency (Cronbach’s alpha = .95) (Steffen and Seney, 2008). The MDS-UPDRS
Part II: Motor Experiences of Daily Living is a self-administered survey of 13 items
with a 0-4 rating for a range from 0 to 52 with a higher score indicating a higher level
of severity and disability.
The Parkinson's Disease Fatigue Scale (PFS-16) is a self-report scale that
measures fatigue, one of the non-motor symptoms associated with Parkinson's, and
measures the presence of fatigue and its impact on daily function (Brown, Dittner,
Findley, and Wessely, 2005). PwPD answer 16 questions on a 5 point Likert scale
ranging from 1 - “strongly disagree” to 5 - “strongly agree” with an average score of
greater than 3.3 identifying those individuals perceiving fatigue to be a problem. This
scale has been determined to have excellent internal consistency (Cronbach’s alpha =
.98) and reliability (ICC = .83) (Brown et al., 2005).
Depression, also a common complaint among PwPD, was measured using the
Geriatric Depression Scale (GDS – 30), a thirty item self-report, yes/no screening
instrument for depression in the elderly (Yesavage et al., 1982). The GDS is short and
easily understood, making it appropriate for use in both clinical research and routine
clinical care as a screening instrument for depression in elderly PD patients (Schrag et
al., 2007). It focuses on the psychological aspects and social consequences of
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depression, avoiding symptom overlap with medical disorders, such as PD, or aging in
general. Each question on the GDS-30 can only be scored “0” or “1,” for a total score
of 30. The higher score indicating higher severity of depression (normal 0-9; mild
depressive 10-19; severe depressive 20-30). It reports high internal consistency
(Cronbach’s alpha = .92) (Ertan et al., 2005).
Finally, to capture the participant’s perception of quality of life, the
Parkinson’s Disease Questionnaire-39 (PDQ-39), a self-report quality of life
questionnaire used to assess HRQoL in individuals with PD. (Peto et al., 1995; Hagell,
Whalley, McKenna, and Lindall, 2003; Hagell and Nygen, 2007). This questionnaire
is composed of 39 items which are rated on a 5 point Likert scale as 0 – “Never” to 4 –
“Always”. The set of 39 questions creates eight domains or scales including mobility
(ten items), activities of daily living (eight items), emotional well-being (six items),
stigma (four items), social support (three items), cognition (four items),
communication (three items), and bodily discomfort (three items) with each scale
totaled and transformed to a range of 0 (best; no problem) to 100 (worst; maximal
problem). These eight domains can be reported as a health profile which offers more
detailed information or as a summary (PDQ-39SI) in which the eight domain scores
are transformed into a summary index score which can be used to reflect an overall
impact of PD (Jenkinson and Peto, 1997; Peto, Jenkinson, and Fitzpatrick 1998).
PDQ39 Summary index scores were used for analysis in this study.
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Neurobiological Measures
Blood sampling for serum brain-derived neurotrophic factor (sBDNF) was
performed at each assessment time point during the study (BASE, EOT, EOT+4).
Subjects reported to the phlebotomy lab at URI, blood was collected (non-fasting)
from the antecubital vein in sterile serum separator tubes. Samples were kept at room
temperature for 20 minutes to allow for clotting and then centrifuged for 10 minutes at
4 degrees Celsius. Serum samples were separated into aliquots and then stored at -80
degrees Celsius until analysis. Once all samples were collected analysis was
completed according to manufacturer’s guideline for ELISA (ABCAM, 2019) at the
RI Idea Network of Biomedical Research Excellence (INBRE) lab located on the URI
campus. Assays were performed in triplicate, blinded to the clinical status of the
participant. Concentrations are expressed as pg/mL and lower detection limits for all
analyzed molecules were 10 pg/mL.

Participation and Adherence Measures
Log of exercise program/treatment protocol as well as an activity log was
maintained by the participant throughout the study. A Post Intervention Participant
Survey was also administered to capture participant’s perception of the treatment
intervention, its potential self-perceived benefits, and feedback to the researchers
regarding the study as a whole. (See Appendix F)
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Statistical Analysis
Statistical analyses were completed using SPSS V26. First, univariate distributions
were examined to provide insight into participant characteristics and ensure that
variables were appropriately distributed for the analysis (i.e. skewness, kurtosis <
|1.0|). Multilevel modeling was used to examine the effects of treatment while
controlling for expected covariates. The structure to the analysis included two levels
so that observations were nested in participants. There was a total of three timepoints
(i.e. BASE, EOT, EOT+4) on each of nine participants for a total of 27 observations.
Outcome variables included the mobility measures (UPDRS III score, FGA,
MiniBEST, gait speed, step length, and TUG), psychometric measures (ABC, PDQ39, GDS-30, and PFS-16), and a neurobiological measure (sBDNF). Covariates
included the following: Age; Gender; Education level; Years with PD; H&Y Rating;
PD subtype; UPDRS Initial Score; LEDD. The missing observations were addressed
by multiple imputation. Ten imputations for sBDNF were sampled from a multivariate
normal distribution and adjusted by Bartlett's method. The results were averaged for
the final multilevel model estimates (Little & Rubin, 2002).
The focus of the analysis was on the treatment effect parameters. It was
hypothesized that there would be a meaningful improvement in functional mobility
and HRQoL measures in PwPD from BASE to EOT. It was further hypothesized that
there would be a meaningful improvement from BASE to EOT+4 even though it may
be reduced compared to immediately following treatment. The model, as described
above, predicted means at BASE, EOT, and EOT+4 were estimated to assess the
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efficacy of treatment. The percentage change in symptoms was reported as an
additional metric of treatment effects.
Challenges in conducting research with PwPD lie in the high variability of
disease manifestation and progression and inconsistency in how data are reported
across studies. This can sometimes lead to clinically relevant effects being missed
during aggregation of data or for statistically significant results to be reported that
have no substantial clinical implications. It is for this reason that minimal clinically
important difference (MCID), which determines whether a medical intervention
improves perceived outcomes in patients, and minimal detectable change (MDC), an
estimate of the smallest amount of change that can be detected by a measure that
corresponds to a noticeable change in ability (Ramprasad 2010) for outcome measures
were evaluated at the individual and group level in addition to statistical analysis.
Statistical significance below an alpha level of 0.05 as well as MCID or MCD
in measurements were taken as evidence of treatment efficacy. (Table 3: Outcome
Measures Summary with MCID and MDC).
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CHAPTER 4

RESULTS

This study examined the effects of LSVT BIG on functional and health related
quality of life (HRQoL) measures in people with Parkinson’s disease (PwPD) and
investigated the potential relationship with changes in serum brain derived
neurotrophic factor (sBDNF).
Results of mobility and psychometric dependent variables are presented
individually and by group using multilevel modeling. Statistical significance was set at
a = .05 throughout the paper unless otherwise noted. Minimal clinically important
difference (MCID) and minimal detectable change (MDC) were identified, for those
measures where they existed, at the individual participant and group level. Percent
changes between each timepoint are also listed.

Demographic and Initial Assessment Measures
A total of twelve participants were screened for the study. Two people did not
meet inclusion criteria due to surgery for deep brain stimulation and one person could
not obtain transportation to the clinic for assessment or treatment. A total of nine
participants (n=9) completed BASE measurements, the full 4-week LSVT BIG
treatment protocol, EOT assessments, and follow up EOT+4 assessments.
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Intervention
The LSVT BIG treatment protocol was completed by all nine participants.
There was a 0% attrition rate although one participant completed a baseline
assessment, started the LSVT BIG protocol for one week, and then reported a back
injury and subsequent pneumonia unrelated to the research activity. Their participation
was placed on hold for 2 months and then a full restart/reassessment completed with
no data from first assessment included in the data analysis. The average number of
days from BASE to starting treatment was six although one individual had an
unexpected delay to start of treatment (19 days).

Compliance
All participants completed the full LSVT BIG treatment protocol of four visits
a week for four weeks for a total of 16 individual one-hour treatment sessions
delivered in one month. Adherence to homework during the treatment period was
difficult to fully assess as participants verbally reported completing their homework
and additional sets of exercises on the day they received their treatment and two times
a day on the days they did not come into the clinic. However, their written homework
logs were inconsistent with this verbal report. Participants were instructed to continue
their LSVT BIG exercises daily during the period between completion of treatment
and follow up assessments that took place four weeks later. All but one participant
returned complete homework logs at assessment EOT+4. Participants adhered to their
homework 72.77% of the time averaging 20.28 sessions out of a possible 28 sessions
during this time period.
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Functional Mobility Measures
Statistically significant changes were identified between BASE and EOT+4 in
four of the six primary outcome measures including the MDS-UPDRS Part III: Motor
Examination (p=.046), FGA (p=.010), MiniBEST (p=.045), and step length (p=.051).
No significant changes in gait speed (p= .369) or TUG (p=.831) at EOT+4 were
identified. None of the mobility measures were significant at the EOT time point
[UPDRS III: Motor (p=.684), FGA (p=.10), MiniBEST (p=..40), TUG (p=.165), gait
speed (p= .096), and step length (p=.786)].
Minimal clinically important difference and MDC were identified in a variety
of participants across the UPDRS-III Motor, gait speed, and FGA scores at both the
EOT and EOT+4 timepoints but was only identified in the UPDRS-III Motor score (4.406) at the group level at EOT+4. (Table 4: UPDRS-III Results; Table 5: FGA
Results; Table 6: MiniBEST Results; Table 7: TUG Results; Table 8: Step Length
Results; Table 9: Gait Speed Results)
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Table 4: Unified Parkinson’s Disease Rating Scale (UPDRS) -III Results
ID

Subtype

UPDRS - III
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

15

11

-4

9

-6

2

TD

28

29

1

22

-6

3

PIGD

15

15

0

7

-8

4

PIGD

25

17

-8

19

-6

5

TD

26

16

-10

18

-8

6

Indeter

28

38

10

35

7

7

PIGD

50

36

-14

52

2

8

PIGD

29

16

-13

15

-14

9

PIGD

26

40

14

17

-9

26.964

26.065

-0.899

22.558

-4.406

Average
P value

0.684

0.046

CI - LL

22.937

21.235

18.148

CI - UL

30.910

30.895

26.968

% Change
MCID Improvement (- 3.25)

-3.33%
MCID Decline (+4.63)

-16.34%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit;
EOT=end of treatment; EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC =
minimal detectable change; PIGD=posture instability gait dominant; TD=tremor dominant
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Table 5: Functional Gait Assessment (FGA) Results
ID

Subtype

FGA
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

30

30

0

30

0

2

TD

28

30

2

27

-1

3

PIGD

28

27

-1

29

1

4

PIGD

22

19

-3

18

-4

5

TD

13

22

9

25

12

6

Indeter

22

23

1

23

1

7

PIGD

3

6

3

6

3

8

PIGD

11

18

7

18

7

9

PIGD

22

25

3

29

7

22.599

24.201

1.602

25.104

2.505

Average
P value

0.100

0.010

CI - LL

20.87

22.126

23.21

CI - UL

24.329

26.275

26.998

% Change
MDC Improvement (+ 4)

7.09%
MDC Decline (- 4)

11.08%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit;
EOT=end of treatment; EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC =
minimal detectable change; PIGD=posture instability gait dominant; TD=tremor dominant
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Table 6: Mini Balance Evaluation System Test (MiniBEST) Results
ID

Subtype

MiniBEST
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

26

27

1

27

1

2

TD

24

24

0

26

2

3

PIGD

26

26

0

26

0

4

PIGD

19

18

-1

19

0

5

TD

15

23

8

22

7

6

Indeter

22

22

0

23

1

7

PIGD

12

8

-4

8

-4

8

PIGD

13

18

5

18

5

9

PIGD

22

23

1

25

3

21.916

22.504

0.588

23.308

1.392

Average
P value

0.400

0.045

CI - LL

20.651

20.987

21.923

CI - UL

23.18

24.021

24.693

% Change
MDC Improvement (+ 5.52)

2.68%
MDC Decline (- 5.52)

6.35%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit;
EOT=end of treatment; EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC =
minimal detectable change; PIGD=posture instability gait dominant; TD=tremor dominant
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Table 7: Timed Up and Go (TUG) Results
ID

Subtype

TUG (sec)
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

7.94

9.14

1.2

8.59

0.65

2

TD

12

11.44

-0.56

11.14

-0.86

3

PIGD

9.25

9.4

0.15

8.37

-0.88

4

PIGD

9.98

12.6

2.62

10.61

0.63

5

TD

15.55

13.18

-2.37

11.68

-3.87

6

Indeter

11.32

14.33

3.01

11.45

0.13

7

PIGD

20.06

18.72

-1.34

23.56

3.5

8

PIGD

17.6

14.49

-3.11

13.3

-4.3

9

PIGD

8.79

8.04

-0.75

9.91

1.12

11.971

12.802

0.831

12.043

0.072

Average
P value

0.165

0.899

CI - LL

10.9

11.518

10.87

CI - UL

13.042

14.087

13.21

% Change
MDC Improvement (-4.85)

6.94%
MDC Decline (+4.85)

0.60%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit;
EOT=end of treatment; EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC =
minimal detectable change; PIGD=posture instability gait dominant; TD=tremor dominant
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Table 8: Gait Speed Results
ID

Subtype

Speed m/s
Change
BASE

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

EOT

at EOT

Change
EOT+4

Overall

1

TD

1.372

1.490

0.118

1.317

-0.055

2

TD

0.911

1.109

0.198

1.052

0.141

3

PIGD

1.524

1.277

-0.247

1.329

-0.195

4

PIGD

0.914

0.997

0.082

1.027

0.113

5

TD

0.768

0.899

0.131

0.991

0.223

6

Indeter

0.951

1.003

0.052

0.997

0.046

7

PIGD

0.418

0.567

0.149

0.259

-0.158

8

PIGD

0.646

0.899

0.253

0.829

0.183

9

PIGD

1.301

1.274

-0.027

1.378

0.076

Average

1.118

1.197

P value

0.079

1.159

0.096

0.369

CI - LL

1.037

1.116

1.079

CI - UL

1.198

1.277

1.24

% Change
MDC Improvement (+ .06 m/s)

7.04%
MDC Decline (- .06 m/s)

0.041

3.67%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit;
EOT=end of treatment; EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC =
minimal detectable change; PIGD=posture instability gait dominant; TD=tremor dominant
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Table 9: Step Length Results
ID

Subtype

Step (cm)
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

60.96

76.20

15.24

71.73

10.77

2

TD

53.14

60.96

7.82

55.37

2.24

3

PIGD

67.74

67.72

-0.03

67.72

-0.03

4

PIGD

50.80

46.74

-4.06

53.01

2.21

5

TD

50.80

53.01

2.21

55.42

4.62

6

Indeter

71.63

67.74

-3.89

76.20

4.57

7

PIGD

30.48

30.48

0.00

26.42

-4.06

8

PIGD

34.82

40.64

5.82

46.89

12.07

9

PIGD

71.70

72.49

0.79

76.20

4.50

60.27

60.68

0.41

63.19

2.92

Average
P value

0.786

0.051

CI - LL

57.54

57.40

60.20

CI - UL

63.00

63.96

66.18

% Change
MDC Improvement (N/A)

0.67%
MDC Decline (N/A)

4.84%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit;
EOT=end of treatment; EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC =
minimal detectable change; N/A = Not available; PIGD=posture instability gait dominant; TD=tremor
dominant

61

Psychometric measures
Participants made statistically significant changes at EOT (p=.021) and EOT+4
(p=.001) on the Activities-specific Balance Confidence (ABC) measure despite not
meeting MDC for the group mean change. No statistically significant change was
identified in the PD Quality of Life-Summary Index (PDQ-SI; p=.573; p=.293),
Geriatric Depression Scale (GDS; p=.063; p=.224), or the Parkinson’s Fatigue Scale
(PFS; p= .678; p=.885) at EOT or EOT+4 respectively.
A MDC was found for several individuals for the ABC and PDQ-SI at both
EOT and EOT+4. There was an MDC for the group mean change for PDQ-SI at
EOT+4. No MDC has been established for the GDS or PFS but two of the five
individuals who scored in the mildly depressed range (10-19) on the GDS at BASE
improved enough to move into the range identified as normal (0-9) at EOT and
maintained that improvement through to EOT+4. A similar pattern was seen with a
PFS score with one of the four individuals who identified fatigue as a problem (>3.30)
at BASE improved to the normal range at EOT and maintained their improvement at
EOT+4. (Table 10: Activities-specific Balance Confidence (ABC) Results; Table 11:
PD Quality of Life-Summary Index (PDQ-SI) Results; Table 12: Geriatric Depression
Scale (GDS) Results; Table 13: Parkinson’s Fatigue Scale (PFS) Results)
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Table 10: Activities-specific Balance Confidence Scale (ABC) Results
ID

Subtype

ABC
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

98.75

96.88

-1.88

99.38

0.62

2

TD

74.69

88.13

13.44

85.00

10.31

3

PIGD

87.50

96.88

9.38

96.56

9.06

4

PIGD

68.75

80.00

11.25

85.63

16.88

5

TD

70.00

64.38

-5.62

74.38

4.38

6

Indeterminate

83.75

83.13

-0.62

82.50

-1.25

7

PIGD

54.38

80.63

26.25

69.06

14.69

8

PIGD

49.38

65.00

15.63

70.00

20.63

9

PIGD

86.88

80.63

-6.25

91.25

4.38

Average

(Inferential)

81.10

86.60

5.50

89.30

8.20

P value

0.021

0.001

CI - LL

77.10

81.70

84.80

CI - UL

85.20

91.50

93.70

% Change
MDC Improvement (+ 11.12)

6.78%%
MDC Decline (- 11.12)

10.11%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit; EOT=end of treatment;
EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC = minimal detectable change; PIGD=posture
instability gait dominant; TD=tremor dominant
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Table 11: Parkinson’s Disease Quality of Life – Summary Index (PDQ-SI) Results
ID

Subtype

PDQ-SI
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

9.6

5.8

-3.8

5.1

-4.5

2

TD

14.7

17.3

2.6

10.9

-3.8

3

PIGD

5.1

1.3

-3.8

3.2

-1.9

4

PIGD

15.4

16.0

0.6

12.2

-3.2

5

TD

24.4

30.8

6.4

12.8

-11.6

6

Indeterminate

31.4

32.1

0.7

34.0

2.6

7

PIGD

35.3

26.9

-8.4

41.0

5.7

8

PIGD

38.5

34.0

-4.5

32.7

-5.8

9

PIGD

17.9

16.7

-1.2

15.4

-2.5

Average

(Inferential)

20.88

21.79

0.90

19.24

-1.64

P value

0.573

0.293

CI - LL

17.96

18.28

16.04

CI - UL

23.81

25.29

18.63

% Change
MDC Improvement (- 1.6)

4.33%
MDC Decline (+1.6)

-7.85%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit; EOT=end of treatment;
EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC = minimal detectable change; PIGD=posture
instability gait dominant; TD=tremor dominant
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Table 12: Geriatric Depression Scale (GDS) Results
ID

Subtype

GDS-30
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

1

2

1

2

1

2

TD

7

7

0

4

-3

3

PIGD

0

0

0

0

0

4

PIGD

10

10

0

14

4

5

TD

10

9

-1

6

-4

6

Indeterminate

11

10

-1

13

2

7

PIGD

14

2

-12

5

-9

8

PIGD

11

12

1

11

0

9

PIGD

7

5

-2

7

0

Average

(Inferential)

6.85

4.87

-1.98

5.62

-1.22

P value

0.063

0.224

CI - LL

4.97

2.62

3.57

CI - UL

8.72

7.12

7.68

% Change
MDC Improvement (N/A)

-28.91%
MDC Decline (N/A)

-17.85%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit; EOT=end of treatment;
EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC = minimal detectable change; N/A = Not available;
PIGD=posture instability gait dominant; TD=tremor dominant
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Table 13: Parkinson’s Fatigue Scale (PFS) Results
ID

Subtype

PFS
Change

I
N
D
I
V
I
D
U
A
L

G
R
O
U
P

Change

BASE

EOT

at EOT

EOT+4

Overall

1

TD

1.1

1.0

-0.06

2.3

1.19

2

TD

2.8

3.0

0.13

2.9

0.05

3

PIGD

1.1

1.0

-0.06

1.1

0.06

4

PIGD

2.6

2.5

-0.06

1.8

-0.81

5

TD

3.1

3.4

0.38

2.9

-0.19

6

Indeterminate

4.3

3.5

-0.81

3.9

-0.38

7

PIGD

3.4

2.9

-0.50

3.3

-0.13

8

PIGD

4.1

3.5

-0.56

3.8

-0.25

9

PIGD

3.3

3.2

-0.13

2.7

-0.63

Average

(Inferential)

2.64

2.59

-0.06

2.62

-0.02

P value

0.678

0.885

CI - LL

2.39

2.28

2.35

CI - UL

2.90

2.89

2.90

% Change
MDC Improvement (N/A)

-2.19%
MDC Decline (N/A)

-0.72%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval upper limit; EOT=end of treatment;
EOT+4=4 weeks after end of treatment; Indeter=indeterminant; MDC = minimal detectable change; N/A= Not available;
PIGD=posture instability gait dominant; TD=tremor dominant
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Neurobiological Measure
Blood samples were obtained from seven participants at BASE. The blood
draws on two participants were unsuccessful at BASE and no further attempts were
made to obtain samples. Six samples were drawn at EOT and one was not successful.
Five samples were obtained at EOT+4. This resulted in a total of 18 samples from a
potential of 27. The assays were performed in triplicate with concentrations of sBDNF
expressed as pg/mL. Randomly generated values for the missing data using multiple
imputation along with Bartlett’s method (Little & Rubin, 2002) allowed for these data
to be included in the multi-level modeling analysis.
The mean for BDNF levels at BASE was 995.03 pg/mL (95% CI 812.6 pg/mL
to 1087.44 pg/mL) and showed a 2% decline at EOT (p=.802) and an overall 23.02%
decline from BASE to EOT+4 which was statistically significant (p=.005). (Table 14:
Serum Brain Derived Neurotrophic Factor (sBDNF) Measures)
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Table 14: Serum Brain Derived Neurotrophic Factor (sBDNF) Results
ID

Subtype

BDNF
Change
BASE

1

TD

2

TD

3

PIGD

598.414

4

PIGD

5

TD

6

Indeter

7

PIGD

8

PIGD

9

PIGD

Average

1044.252

EOT

at EOT

Change
EOT+4

Overall

1017.402

-26.85

1012.474

-31.778

1009.0935 1013.8105

4.717

986.2765

-22.817

333.729

-264.685

386.298

-212.116

918.144

1017.342

99.198

311.767

-606.377

950.936

871.917

-79.019

1000.608
-

-

-

-

-

-

-

-

-

-

-

-

-

-

1067.397

1030.307

995.026

931.157

P value

-37.09
-63.869

1017.463
731.289

0.802
812.609

766.344

580.823

CI - UL

1087.443

1095.971

881.755
-1.99%

MDC Decline (N/A)

MDC Improvement (N/A)

-263.737
0.005

CI - LL

% Change

-49.934

-23.02%
P < .05

Note: Base=baseline; CI-LL=confidence interval lower limit; CIUL=confidence interval
upper limit; EOT=end of treatment; EOT+4=4 weeks after end of treatment;
Indeter=indeterminant; N/A= Not available; PIGD=posture instability gait dominant;
TD=tremor dominant
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Correlation analysis revealed only weak positive relationships between sBDNF
and the UPDRS-III (r= 0.1988) and weak negative relationship between FGA (r = 0.207), MiniBEST (r = -0.26), step (r = - 0.28), and ABC (r= -0.24). (Figure 5: Serum
Brain Derived Correlates)

Figure 5: Serum Brain Derived Neurotrophic Factor (sBDNF) Correlates
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TUG
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Step Length
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Speed
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UPDRS 3

0.2

PDQ-SI

0.3
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-0.4
Increases in these measures = worsening

Increases in these measures = improvement

Note: ABC=Activity Specific Balance Confidence Scale; FGA=functional gait assessment;
GDS-30=Geriatric Depression Scale; MiniBEST=miniBEST test; PDQ-SI=Parkinson’s
Disease Quality of Life Summary Index; PFS=Parkinson’s Fatigue Scale; TUG=timed up
and go
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CHAPTER 5

DISCUSSION

This study investigated the impact of LSVT BIG, an intensive, whole-body,
amplitude-based training protocol, on functional mobility, quality of life, and markers
of neuroplasticity in PwPD. In light of limited treatment options for PwPD, it is
important to establish effective evidence-based treatment interventions within the PT
discipline along with valid, sensitive outcome measures. This treatment efficacy study
used a within-subject multiple baseline design (A-B-A-A). The findings demonstrated
statistically significant improvements in the gait measures of step length and gait
speed, confidence with balance, and improved quality of life measures but not in
TUG, fatigue, or depression measures by EOT+4. These findings are consistent with
our first and second hypothesis that exercise intervention using LSVT BIG would
produce positive statistically significant changes in mobility outcomes and quality of
life measures in PwPD. The third hypothesis that there would be measurable changes
in sBDNF levels following LSVT BIG was not supported. Serum BDNF declined
which was opposite the direction expected. The fourth hypothesis that there would be
correlations between sBDNF and functional measures was also not supported because
no significant correlations were found.
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Hypothesis 1: Exercise intervention using LSVT BIG will produce positive statistically
significant changes in functional mobility outcome measures in PwPD
This study supports LSVT BIG as an effective behavioral treatment
intervention for PwPD implemented in a university clinic with people experiencing
mild to moderate disease severity that positively impacts functional mobility.
Statistically significant changes were identified at the group level between
BASE and EOT+4 in four of the six primary outcome measures including the MDSUPDRS Part III: Motor Examination, Functional Gait Assessment, MiniBEST, and
step length all contributing to an overall improved mobility presentation. (Figure 6:
Functional Mobility Outcome Measures; Figure 7: Gait Outcome Measures)
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Movement Disorder Society -Unified Parkinson’s Disease Rating Scale (MDSUPDRS) – III Motor Scale
Significant improvements were identified in the MDS-UPDRS III Motor score
at EOT+4 (8 weeks from BASE) and were consistent with findings reported in other
LSVT BIG studies (Dashtipour et al., 2015; Ebersbach et al., 2010; Ebersbach et al.,
2014; Ebersbach et al., 2015). Similar to the current study, Dashtipour et al. (2015)
reported no significant improvements at EOT while none of the Ebersbach et al.,
studies (2010; 2014; 2015) reported data from EOT assessments. Two other LSVT
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BIG studies identified MCID at EOT and EOT+8 (Millage et al., 2017; Ueno et al.,
2017) but did not complete statistical analysis while one study did not collect MDSUPDRS scores (Farley et al., 2005).
Changes in the MDS-UPDRS-III Motor score reported in studies of
interventions employing similar “intensive” exercise have been positive but not
consistently significant. King et al., (2015) utilized the ABC (Agility Boot Camp)
protocol to compare delivery setting – Home exercise program, group class, and
individual treatment - which resulted in an improvement in the MDS-UPDRS III
scores but not to a level of significance or meeting MCID. A study investigating high
intensity boot camp compared to usual care found significant improvements in MDSUPDRS III scores at the EOT (8 weeks from baseline) in both groups but these gains
were not maintained at six months following treatment in either group (Landers et al.,
2019). A systematic review of PD and intensive exercise by Uhrbrand et al. (2015)
subdivided results from 10 studies into resistance training, endurance training, and
“other intensive” training and reported results across those categories as utilizing
MDS-UPDRS III scores. The analysis of the results were mixed with all three
resistance studies and one “other intensive” training study reporting significant
improvement and all four endurance studies and two of the “other intensive” training
studies reporting no significant change as measured by MDS-UPDRS III scores.
Variability of treatment impact on PwPD’s MDS-UPDRS III score across
studies may be a reflection of the wide variability that exists in type of intervention,
exercise dosage, and timing of outcome assessments as summarized in the Cochrane
review comparing treatment interventions in PwPD (Tomlinson et al., 2012).
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Tomlinson et al. (2012) reported 17 of 43 studies reported MDS-UPDRS III data and
14 studies revealed no difference in the motor score between treatments but did not
indicate if there was any significant improvement across the treatment arms being
compared. Three studies reported significant improvement MDS-UPDRS III scores
when compared with an alternative treatment intervention, one of which was the
LSVT BIG Berlin study (Ebersbach et al., 2010) and two additional studies (Ridgel et
al., 2009; Gupta et al., 2011).
The MDS-UPDRS is the international rating system identified as the gold
standard in assessing PwPD. The items on this scale and some of its sections can be
utilized to identify subtypes of PD such as tremor dominant (TD) and postural
instability gait disturbance (PIGD) (Stebbins et al., 2013), freezing of gait, and impact
of dyskinesia. It has been demonstrated to have excellent internal consistency (a =
.93) and validity (r = .96) as a clinical outcome measure and can be administered in a
timely manner (Goetz, et al., 2008). The availability of a clinician who is trained to
administer and score the scale may be its primary limitation in its broader application
in treatment efficacy studies.

Functional Gait Assessment (FGA) and Mini Balance Evaluation System Test
(MiniBEST)
The FGA and the MiniBEST tests were used to evaluate mobility. The FGA
focuses on postural stability and dynamic gait (Weber et al., 2016) while the
MiniBEST focuses on dynamic balance, postural responses, and anticipatory
transitions (Franchignoni et al., 2010). In this cohort, the FGA appeared to be more
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sensitive to change with two participants meeting MDC for improvement and group
mean statistical significance at both EOT and EOT+4 while the MiniBEST identified
just one participant as meeting MDC and a group mean statistical significance only at
EOT+4. The difference in sensitivity did not appear to be related to a ceiling effect.
(Table: 5; Figure 6:Functional Mobility Outcome Measures)
This finding is consistent with the only other LSVT BIG study that used the
FGA (Millage et al., 2017) which reported MCID in three of the nine PwPD. Some of
the LSVT BIG studies included generalized gait measures (gait speed, TUG, and step
length) but none, except Millage et al. (2017) included a specific balance measure.
The finding is also consistent with the report of significant improvement in the
MiniBEST score in PwPD receiving individual and group Agility Boot Camp training
(King et al., 2015), highly challenging balance training (Leavy et al., 2020), and high
intensity boot camp (Landers et al., 2019).
It is disappointing that so few studies appear to integrate specific balance
assessments in their outcome measures given the significant issue with postural
instability, balance confidence, and falls that PwPD experience. Balance and gait have
been identified as independent domains when assessing mobility in PwPD. A single
measure of static conditions cannot reliably predict dynamic postural instability as
seen in gait activities (Horak et al., 2016). It has been suggested that clinicians should
consider outcome measures at each of the International Classification of Function
(ICF) levels to direct treatment intervention (King et al., 2013) rather than only
utilizing body structure (i.e. MDS-UPDRS III) and function level of the ICF in
research.
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A strength of the current study is the inclusion of two separate balance
measures to address dynamic gait and postural instability. These findings, related to
improvements in FGA and MiniBEST following LSVT BIG treatment, contribute to
the body of knowledge regarding the choice of clinical outcome measures a clinician
may opt for when treating PwPD. Findings suggest the FGA may be a more precise
measure for PwPD, however, it is possible that the subtype of PD (tremor dominant
(TD) versus postural instability gait disturbance (PIGD)) may play a role in supporting
one measure over another. These findings may suggest that LSVT BIG is more
effective in addressing gait impairments compared with balance disturbance but
further investigation is needed.

Gait Speed, Step Length, and Timed Up and Go (TUG)
Gait speed, step length, and turning speed are closely integrated measures of
gait performance. They have been identified as predictors of quality of life, morbidity,
and mortality in PwPD (Ellis et al., 2011), activities of daily living limitations in
PwPD (Tan et al., 2012), and impending disability in older adults (Ellis et al., 2016).
Often these parameters are measured only in part and independent of each other in
both the research and clinical setting, yet they may offer a more accurate and clinically
meaningful interpretation when considered together.
Gait speed, the driver of an individual’s performance on the TUG, has been
identified as a key predictor of falls in PwPD when it is less than 1.1 m/s (Lindhom et
al., 2018). Only three of the nine participants had a gait speed >1.1 m/s at BASE.
None of the participants improved above the 1.1 m/s threshold at EOT. Six
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participants remained in the increased falls risk category. This finding was consistent
with Ueno et al. (2017) study, which showed no change in gait speed as measured by
10 meter walk, a finding that is in contrast to several other LSVT BIG studies
reporting significant improvements in gait velocity or improvement in 10 meter walk
(Ebersbach et al., 2010; Ebersbach et al., 2015; Farley and Koshland, 2005; Millage et
al., 2017). This may have been influenced by the high number of individuals that
exhibited somewhat lower gait speed at baseline. (Table: 8)
PwPD often experience an altered gait pattern characterized by short, shuffling
steps. This decreased step length along with decreased gait speed can contribute to
falls. Only one participant in this cohort was assessed with what would be considered
“normal” step length - 79 cm for men (Murray, Drought, and Kory, 1964) and 66 cm
for women (Murray, Kory, and Sepic, 1970) - at BASE and EOT+4. This is consistent
with improved step length reported in Ebersbach et al. (2015), the only LSVT BIG
study reporting step length as a dependent variable.
Impairment of turning during gait and functional tasks is a hallmark
characteristic of PwPD and can contribute to freezing of gait (FOG), decreased
confidence with activities, and loss of balance (LOB) (Curtze et al., 2011).While not
measured individually, turning speed is a measure integrated into the FGA and is
scored on a scale from 0 (severe) to 3 (normal). While only two of the participants in
this study scored within normal range for turn speed at BASE (mild impairment n=4;
moderate impairment n=2; severe impairment n=1) the trend moved towards less
impairment at EOT (normal n=5; mild=3; moderate n=0; severe n=1) with seven
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participants reaching normal turning speed by EOT+4 leaving one participant at mild
and one at moderate impairment.
The TUG did not appear to serve as a sensitive measure of significant change
following treatment intervention in the current study. TUG was assessed as showing
statistical significance in two of the seven LSVT BIG studies (Ebersbach et al., 2010;
Ebersbach et al., 2015) while one study showed no significant changes (Ueno et al.,
2017). Neither Ebersbach et al., (2010; 2015) reported MCID for the TUG as the
changes were fairly small (-.75 sec and -1.3 sec, respectively). Three case series
reports of LSVT BIG excluded from the systematic review discussed earlier all
completed TUG and none showed any significant change at EOT or at any other
follow up assessment (Chatto et al., 2018; Fishel et al., 2018; Janssens et al., 2014).
The results for this study were consistent with these findings - no statistically
significant change in the TUG and none of the participants met the threshold for
MCID which is reported to be 11 seconds (Steffen and Seney, 2008).
Three of the participants in this study scored >14 seconds identifying them for
high falls risk at BASE yet two of them improved to below the cut-off for falls risk
(Podsiadlo 1991) by the EOT+4. Our findings support TUG and gait speed as clinical
tools to identify people at risk for falls but suggest additional measures, specifically
step length and turning speed, to capture changes related to treatment intervention,
provide a more comprehensive clinical picture of the PwPD, and inform clinical
intervention decision making. This study suggests that LSVT BIG may contribute to a
reduction in falls by impacting gait speed, step length, and turning speed potentially
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decreasing the impact of disability in PwPD (Table 7; Table 8; Table 9; Figure 8: Falls
Risk at BASE and EOT+4)

Hypothesis 2: Exercise intervention using LSVT BIG will produce positive statistically
significant changes in psychometric measures including quality of life in PwPD.
This study supports LSVT BIG as an effective behavioral treatment
intervention for PwPD implemented in a university clinic with people experiencing
mild to moderate disease severity that positively impacts quality of life measures.
Characteristics that impact quality of life such as confidence with balance and
mobility and nonmotor symptoms of PD such as fatigue and depression are important
for quality of life in PwPD. The ABC, a measurement of participant perceived
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confidence with a variety of daily activities, was the only measure to reach statistical
significance at EOT and EOT+4 yet MDC improvements were noted at the individual
level for the ABC, PDQ-39 Summary Index, and depression measures. (Table 10,
Table 11, and Table 12; Figure 9: Balance Confidence and Quality of Life and Figure
10: Depression and Fatigue)
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Activities-specific Balance Confidence (ABC)
Confidence with activities as measured by the ABC has been correlated with
turning, pace-related measures, and dynamic stability during gait (Curtz et al., 2016)
which, as discussed in the previous section, have been identified as predictors of
quality of life and mortality (Ellis et al., 2011). The ABC as a tool to measure response
to treatment interventions has been mixed. Two recent studies in PwPD (King et al.,
2015; Leavy et al., 2020) reported ABC results indicating improvements in
participant’s confidence with mobility but was not statistically significant and did not
meet MDC. The findings from the current study found both statistically significant
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changes in the ABC at EOT and EOT+4 at the group level and MDC at the individual
level supporting the ABC as a sensitive measure in PwPD following LSVT BIG.

Health Related Quality of Life (HRQoL)
HRQoL was measured utilizing the PDQ39 and calculated as a summary index
score which reflects the overall impact of PD on quality of life (Jenkinson & Peto,
1997; Peto et al., 1998). Impairment in HRQoL in PwPD is associated with mobility
and function and is positively correlated with increasing disease severity (Schrag et
al., 2000). The PDQ39 is sensitive to changes which tend to matter to the person with
PD but may not necessarily be the focus of clinical assessment which is focused on
impairment (Peto et al., 1998). In other words, progressive motor impairments due to
increasing disease severity (i.e. tremor) is NOT predictive of worsening HRQoL but
worsening physical function/mobility IS (Ellis et al., 2011).
Despite no statistically significant changes, four individuals in this cohort
demonstrated improvement in their PDQ-39SI scores meeting MDC at EOT while six
individuals met MDC at EOT+4 and the group mean change also met MDC at this
time. Two participants demonstrated an MDC decline in HRQoL at each time point.
(Table: 11)
These findings are consistent with the literature that has shown HRQoL
measures to be fairly resistant to change over a short period of time (King et al., 2015;
Park et al., 2014; Ridgel et al., 2009; Schenkman et al., 2012; Speelman et al., 2013).
A few studies have reported improvements (Cugusi et al., 2014; Combs et al., 2013)
but these interventions were more prolonged (9 weeks and 12 weeks, respectively)
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supporting again, the idea that neuroplasticity changes may only be realized over a
more prolonged period of time.
The mobility subdomain on the PQD-39 has been shown to be closely
associated with postural control as measured by the FGA, which may provide
clinicians a useful interpretation of the PDQ39 results even if no significant change is
measured (Ellis et al., 2011).
This study provides insight into the complex relationship among disease
related nonmotor symptoms such as depression and fatigue, disease severity, and
progressive disability. Results suggest that LSVT BIG is an efficacious behavior
treatment intervention that targeted mobility limitations which not only resulted in
improved function but also positively impacted HRQoL for PwPD.

Parkinson’s Fatigue Scale (PFS)
Fatigue is the most common non-motor symptom of PD, rated as the most
disabling symptom by 33% of PwPD and within the top three most disabling by 50%
of PwPD (Herlofson et al., 2017). It also has the highest negative impact on HRQoL
measures and yet receives the least amount of focus in research, clinical assessment,
and treatment (Herlofson et al., 2017). The pathology of fatigue in PwPD remains
elusive although the basal ganglia pathways appear to be implicated, specifically the
ventral striatum, caudate, and putamen and the uptake of serotonin (Friedman et al.,
2016). There were no significant changes noted in levels of fatigue. Scores >3.3 fall
into a category describing fatigue as a problem. The mean level of fatigue for the
cohort was 2.5. There is no MDC established for the PFS but two individuals scored
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above the cutoff of 3.3 at BASE and moved below the cutoff at EOT and maintained
the improvement at EOT+4. No rigorous trials have been conducted yet the leading
nonpharmacological treatment that has been suggested for PwPD is exercise, given
that patients often report they feel energized after exercise (Friedman et al., 2016).
(Table 13)
It is difficult to interpret these findings in the context of the current literature as
so few studies measure fatigue. The extensive Cochrane review comparing different
PT exercise intervention studies identified that although there was a wide variety of
measures across all studies most were PT and PD focused (Tomlinson et al., 2012).
The finding in this study is consistent with one recent trial that reported a significant
improvement in perceived fatigue immediately following a high intensity boot camp
(HIBC) compared with usual care (Landers et al., 2019) and the effects of a physical
activity program in PwPD (Cugusi et al., 2014). Interestingly, individuals in the HIBC
group continued to report lower fatigue levels at the six month follow up assessment
while the usual care group reported worse fatigue. This may represent a broadly
interpreted level of neuroprotection and an overlooked impact of intensive behavior
treatments on one of PwPD most disabling symptoms.
Depression
The presentation is similar for depression. The prevalence of depression has
been found to be as high as 36.3% for minor depression and 12.9% for major
depression in PwPD (van Der Hoek et al., 2011). Unfortunately, it is estimated that
only 20% of those individuals will receive treatment for their symptoms which can
lead to reduced quality of life and increased risk for disability (Frisina et al., 2008;
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Schrag et al., 2000). In contrast to these reports of limited treatment for depression,
80% of this cohort that reported symptoms consistent with mild depression on the
GDS were receiving some type of anti-depressant medication.
Depression can be a psychosocial response to stress of living with a
degenerative disease and impending disability, yet it is also thought to have a
biomedical basis related to the disease process of PD itself (Frisina et al., 2008). The
catecholamine system, specifically the locus coeruleus producing norepinephrine and
the substantia nigra producing dopamine, has been implicated in major depression in
PwPD as observed in postmortem evaluation of brain tissue (Frisina et al., 2009).
Diagnosis and treatment are important early in the disease process to preserve function
and quality of life.
Participants in the current study scored in the normal (n=4) and mild
depression (n=5) range at BASE however at EOT and EOT+4 this had improved to
n=6 in the normal range and only n=3 in the mild depression range. Depression has
not been consistently measured in behavioral intervention studies. One study
implementing an exercise program similar to LSVT BIG in its intensity, duration, and
1:1 therapist delivery (King et al., 2015) and another evaluating the effects of a
physical activity program in PwPD (Cugusi et al., 2014) both showed significant
improvement in self -reported depression levels.
Results of this study found improvements in ABC at the group level and PDQSI at individual level suggesting that exercise, and specifically an intensive individual
intervention such as LSVT BIG, may exert small but important improvements in
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confidence and quality of life while its influence on depression and perceived fatigue
warrants further research.

Hypothesis 3: There will be measurable changes in sBDNF levels following LSVT BIG
treatment as a result of intensive exercise.
Despite the mechanisms of BDNF not being completely understood it has been
hailed as a biomarker of neuroprotection and neuroplasticity (Cotman et al., 2007) yet
also linked to pathogenesis and neurodegenerative disease (Scalzo et al., 2010;
Ventriglia et al., 2013).
In this cohort, resting sBDNF changed in response to the LSVT BIG exercise
intervention which identified a 10.11% decline at EOT (p=.264) and an overall
30.94% decline from BASE to EOT+4 which was statistically significant (p=.003) but
in the opposite direction than was expected. This was in contrast to statistically
significant increases in sBDNF identified in four studies of PwPD that showed
increases of 12.6%, 34%, 36%, and 22.7%, respectively (Frazzita et al., 2014;
Marusiak et al., 2015; Angelucci et al., 2016; and Zoladz et al., 2014). This difference
could be related to the type of exercise intervention which may have been more
aerobic in nature as all four of those studies employed stationary cycle or treadmill
training. (Figure 11: Serum Brain Derived Neurotrophic Factor)

86

Hypothesis 4: There will be positively correlated changes between sBDNF level and
functional mobility outcomes measures
Correlation analysis revealed weak negative relationships between sBDNF and
measures that represented functional improvement (i.e. FGA, MiniBEST, step length,
and ABC) and weak positive relationships between sBDNF and measures representing
functional decline (i.e. UPDRS III, PFS, GDS, and PDQ-39 SI) (see Fig. 5 sBDNF
Correlates).
Ventriglia et al. (2013) identified significantly decreased sBDNF associated
with neurodegenerative disease such as Alzheimer’s disease and related dementias
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while significantly increased sBDNF was associated in PwPD with high disease
severity compared with controls. They identified L-dopa as a significant contributing
factor due to the medication’s role in facilitating BDNF release in cortico-striatal
fibers and emphasize the importance of collecting medication information when
studying BDNF response. These studies were baseline measures only and did not
employ any intervention to measure a response to exercise. This is in contrast to a
study by Rocha et al. (2018) which identified neurotrophic factors as unchanged in
PwPD. However, Rocha et al. (2018) evaluated plasma levels in contrast to serum
levels which has been suggested to reflect only freely circulating BDNF while serum
levels reflect stored and freely circulating BDNF (Voss et al., 2017) which can
confound interpretation of results and the ability to compare results.
The current study did not include neurotypical participants for a comparison of
sBDNF to PwPD. Therefore, we cannot determine if sBDNF levels were relatively
high or low at BASE for the participants. Correlation analysis of sBDNF revealed only
weak positive and negative relationships across all variables with the exception of the
PADS-R which was a moderate negative relationship (r= - 0.627) interpreted as higher
sBDNF levels related to lower premorbid physical activity levels. This may be in line
with sBDNF levels reflecting disease state such as hypothesized by Scalzo et al.
(2010) who related low BDNF in early disease states of PD as a sign of pathogenesis
and elevated BDNF later in the disease state as a compensatory mechanism. (Figure 5:
Serum Brain Derived Neurotrophic Factor Correlates)
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Neuroplasticity, Exercise Prescription and Clinical Implications
Linking behavioral and biological measures to support neuroplasticity remains
challenging and open to a myriad of interpretations. The potential meaning in a single
variable change (i.e. sBDNF) at a cellular level is extremely difficult to interpret.
BDNF can be measured in serum, plasma, and cerebral spinal fluid in humans. BDNF
is only one neurotrophic factor among several (i.e. IGF-1 and VEGF) in a cascade of
responses to physiologic influences such as exercise and other confounding factors
such as disease state and medication contribution. It may be that changes in BDNF are
similar to neuroplastic changes that have been discussed in neuroimaging studies in
response to exercise and enrichment. Increased activity and connectivity in fMRI in
association with performance improvement, in a short time period, has been
interpreted by some to represent an acute response representing temporary
neuroplasticity (Amad et al., 2017; Bakhtiari et al., 2017; Rosenberg-Lee et al., 2018).
Decreased connectivity that has been associated with ongoing performance
improvement over a longer time period has been interpreted as improved efficiency of
the system (Everts et al., 2017; Supekar et al., 2015; Yuan et al., 2017). These spatial
and temporal responses may be at play with sBDNF where elevation in sBDNF as
measure immediately following acute exercise is associated with performance
improvement and decreased levels of sBDNF following chronic, longer term exercise
and reflected in resting serum levels are associated with persistent performance
improvements may represent an improved efficiency and decreased disease load on
the system.
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This study reported statistically significant improvements (alpha < 0.05) across
both clinical measure categories in four of the six functional mobility measures and
one of the four psychometric measures but not until EOT+4. Only the ABC was
significant at EOT. This delay of full effect may reflect a different temporal and
spatial pattern for neuroplasticity changes to occur before they become evident as
more global behavioral changes. The furthest time point in all of the LSVT BIG
studies reviewed was sixteen weeks while similar intensive exercise studies assessed
at twelve weeks or less (King et al., 2015; Leavy et al., 2020). Only one study
included a six month follow-up time point (Landers et al., 2019) which supported
improvement at EOT and then a pattern of decline by month six. This is an important
note considering much of the research (and all of our clinical applications) assesses
changes, whether mobility or psychometric, close to the end of a treatment
intervention. These findings identify a need for more routine and longitudinal
assessments.
Parkinson’s disease has been described, as a “complex genetic disorder”
associated with a wide array of genes that exert small effects that align and potentially
trigger the cardinal signs and symptoms (Williams-Gray and Worth 2016; Weiner,
Shulman, and Lang, 2013, p.28). Perhaps this multidimensional perspective in the
development of the disease is one that is also pertinent in the pursuit of the treatment.
We need to ensure that we are not so busy searching for the one “magic solution” that
we miss out on the more realistic multifaceted solutions available. It could be that the
many small effects come from a wide number of “epigenes” – nutrition, sleep,
exercise, social interactions, mental engagement - each exerting a small effect until the
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interventions/solutions align and facilitate the PwPD to move towards improved
function, improved mental health, and better quality of life.
Exercise is one of those “epigenes”. There are several components that guide
exercise as a mover of neuroplasticity. Salience, intensity, frequency, duration, and
setting all come together like the ingredients in a recipe for health. A longitudinal
analysis of National Parkinson Foundation Quality Improvement Initiative Data
(NPFQII) concluded that PwPD who regularly exercised (>2.5 hours/week)
experienced small but positive changes in HRQoL and mobility measures in contrast
to those who did not exercise and experienced a decline in mobility and HRQoL
(Rafferty et al., 2017). This supports the idea of regular exercise as protective of
mobility and HRQoL over time.
LSVT BIG utilizes each of these key principles of neuroplasticity in such as
manner as to recalibrate and steer the PwPD in the direction of restoration. It is clear
from the reported outcomes in this study that LSVT BIG is an effective behavioral
treatment intervention for PwPD. It is less clear as to whether it is one of those
principles or the blend of all of them that contributes to the success the treatment.

Limitations
There are several limitations associated with this study. The participants were
self-selected and part of a convenience sample which may limit the ability to
generalize findings across populations and may represent selection bias. Individuals
served as their own control but a comparison group that did not receive treatment was
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not included in the sample. Since there was only one arm for treatment there was no
randomization. The study had a small number of participants at n=9.
There are limitations inherent to a within subject multi-baseline design (A-BA-A). One limitation is the inability to control for potential confounders which may
bias the results although expanding the number of measures can sometimes assist in
decreasing the impact. Another limitation is that each participant serves as their own
control. A separate control group which receives no treatment would strengthen the
design.
The principal investigator completing the assessments also participated in the
delivery of treatment for some of the participants due to limited access to LSVT
certified clinicians. Although every attempt to blind the rater to time points for
assessments was made whenever possible, bias cannot be completely excluded.
A less restrictive approach was taken in setting inclusion and exclusion criteria
in the recruitment process in order to promote greater ecological validity. The cohort
had a normal distribution with the exception of the H&Y rating. The high distribution
of participants with a H&Y score of 2 (n=7) reflects the ongoing challenge faced in
many studies with PwPD when trying to recruit a diverse cohort. The H&Y scale was
established as a convenient method of assessing disease severity by taking into
account both the clinical features and progression of disability (Hoehn and Yahr 1967)
and is the standard staging system used to describe patient populations second only to
the MDS-UPDRS (Goetz et al., 2004). Goetz et al. (2004) described the distribution of
PwPD across large cohorts with Stage 1 and Stage 5 accounting for the least number
of subjects followed by Stage 4 and that most subjects (52-77%) were Stage 2 and 3.
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This study reflects these identified distributions. Goetz et al., (2004) identified support
for continued use of the H&Y staging as it does serve to describe PwPD, which is an
important in clinical efficacy studies, and it captures important aspects of disease
progression, but its limitations need to be kept in mind.
One option to address the need for an easily understood severity scale was
introduced by Martinez-Martin et al. (2014) who proposed utilizing the MDS-UPDRS
as a measure of disease severity and established cut-off points for each of the four
parts. Applying this severity scale to the current cohort (MDS-UPDRS III: cut-off
scores mild <32, moderate 33 to 58, and severe >59) identifies eight of the participants
in the mild range and only one participant in the moderate range. Interestingly the two
participants identified as H&Y stage 3 were both classified as mild severity. This
classification of disease severity and disability rating appears more accurate in this
cohort compared with the H&Y considering the PwPD identified as moderate disease
severity presented as such based on actual clinical observation by this
researcher/clinician in conjunction with outcome measures. However limitations exist
with this approach first and foremost, the need for an MDS-UPDRS assessment to be
completed and the need for further large scale validation of the cut-off values
(Martinez-Martin et al. 2014).
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CHAPTER 6
CONCLUSION

Recommendations for Future Research
Principles of neuroplasticity are integral to the application of behavioral
interventions aimed at addressing the complex nature of Parkinson’s disease. Exercise
is a behavioral intervention because it exerts broad strokes on the human landscape
and empowers the PwPD to modify symptoms of the disease. It requires a prescription
that follows evidence-based practice. We need to employ a methodical deconstruction
of exercise prescription in our research including the assessment of each component –
type, mode of delivery, frequency, duration, and intensity. Evaluating LSVT BIG with
an alternative dosing schedule would be an important step toward understanding the
roles of dosage (intensity of exercise within one session) and duration of treatment
may play in outcome.
There is not one treatment for all PwPD and treatment efficacy research needs
to identify which therapy is appropriate for specific characteristics of PD. It is
important to report all outcome data for responders and nonresponders. Data from
“nonresponders” may support that a treatment was ineffective or may represent a PD
subtype that requires different interventions. That data might also reflect stabilization
and neuroprotective aspects of a treatment intervention. Complete reporting of data,
even when they appear nonsignificant, can serve to guide future research directions.
Although larger studies are needed, they are not always feasible or investigators may
not have access to large groups of participants. Improved reporting of methodology,
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exercise protocols, consistency in data collection and analysis, and use of more
comprehensive measures following ICF guidelines could improve consistency across
studies. This might facilitate the ability of small n studies to be evaluated in a larger
context such as systematic review and meta-analysis.
Parkinson’s disease has been perceived as a primary motor disease however, it
needs to be kept in mind it is, in fact, a sensory-motor disease that it has many
nonmotor symptoms which impact on PwPD HRQoL. More extensive psychometric
measures need to be utilized both in the clinic and future research to capture important
impact both the disease and treatment (i.e. exercise) may be exerting on depression,
fatigue and other mental health related issues and HRQoL. Research that evaluates the
role of sensory input and integration into movement will also be important to
contribute to our understanding of disease progression as well as the development of
new treatment interventions.
Utilization of the MDS-UPDRS III offers not only direct measures of mobility
but also the ability to extract key components to classify further subtypes of PD such
as tremor dominant (TD) and postural instability and gait disturbance (PIGD)
(Stebbins et al., 2013), freezing of gait (FOG), and impact of dyskinesia. Integrating
MDS-UPDRS III measures whenever feasible and analysis of data related to outcome
measures in consideration with these subtypes may better inform clinical decision
making. Freezing of gait was not assessed separately from the MDS-UPDRS III or
included in the analysis. Since FOG, similar to PD subtype, can significantly impact
an individual’s experience with the disease including mobility and HRQoL, it will be
important to integrate these measures into future studies.
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In light of the delayed time frame from start of treatment to measurable
functional improvement, future longitudinal studies are needed as well as
recommendations for ongoing periodic clinical assessments for PwPD, especially
given the progressive nature of the disease process. This will not only guide clinical
practice but support the reimbursement of these interventions for PwPD.
Compliance remains a challenge, both facilitating it from a clinical perspective
and measuring it from a research perspective. Future studies employing developing
technologies such as smart watches and telehealth may assist in this process. LSVT
BIG has been marketed primarily for PwPD, however, its employment of principles of
neuroplasticity in its treatment approach may prove effective with people with a
variety of neurologic disorders and future research should consider expanding into
these patient populations.

Conclusion
The aim of this study was to investigate the impact of LSVT BIG on the
functional mobility, quality of life, and markers of neuroplasticity in PwPD. This
study is unique in its integration of neurobiological measures with comprehensive
functional and psychometric measures. This study supports the use of LSVT BIG as
an efficacious treatment intervention with PwPD that is associated with significant
improvements in mobility, step length, confidence with balance, HRQoL measures as
well as decreased reports of depression and fatigue. Results associated with sBDNF
levels should be interpreted with caution since the sample was so small and further
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analysis for additional neurotrophic factors, such as vascular endothelial growth factor
(VEGF) and other potential anti-inflammatory markers may be warranted.
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APPENDICES
APPENDIX A
Table of Measures and Timeline
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Table of Measures and Timeline (continued)

99

APPENDIX B

Consent Form for Research
STUDY TITLE
LSVT BIG Exercise-Induced Neuroplasticity in People with Parkinson’s Disease: An Assessment
of Physiological and Behavioral Outcomes
PRINCIPAL INVESTIGATORS
Leslie Mahler, PhD, CCC-SLP
lmahler@uri.edu
Christine Clarkin, DPT
chrisclarkin@uri.edu

Phone: 401-874-2490

Email:

Phone: 401-662-5367

Email:

KEY INFORMATION
Important information to know about this research study:
•

The purpose of the study is to look at how an exercise program designed for people
with Parkinson’s disease (called LSVT BIG) helps movement and walking.

•

You need to have a diagnosis of Parkinson’s disease to be in this study.

•

You need to be able to walk (with or without a device) as well as stand to complete
the exercises.

•

You can NOT have completed the LSVT BIG treatment in the past year or have a
diagnosis of a past heart attack, stroke or other neurologic diagnosis, or surgery for
treatment of Parkinson’s Disease such as a deep brain stimulator.

•

If you choose to join the study, you will be asked to answer some questions and a
therapist will do some tests related to balance and your ability to move and walk.
This will take about 3 hours. This full assessment will occur two more times, the
week after the LSVT BIG treatment and one last time 4 weeks later.

•

You will then come to the physical therapy clinic at URI 4 times a week (for four
weeks) for one hour sessions with a clinician. They will teach you exercises,
movement , and walking activities. They will also give you homework you will do
daily. This is an exercise program that you will end up doing twice a day, every day,
for the 4 weeks (28 days).
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•

If you choose to join the study, you will be asked to submit a blood sample 3 times
(one at each testing time point). This part is optional and will be explained in a
separate consent form that will provide information regarding the blood draw and
why we are asking for a blood sample. You may still join in the LSVT BIG study and
decide not to do of the blood sample at any time.

•

You will be asked to use as a smart watch which will record daily activity, steps, heart
rate, and sleep patterns You may still join in the LSVT BIG study and not do this part
or decide to stop this at any time.

•

Risks or discomforts from this research: There is minimal risk associated with this
study beyond those you might have with any exercise program, which can include
fatigue or muscle soreness.

•

This study will provide the researchers with information about the effect of this
exercise treatment in patients with Parkinson’s disease. You may experience some
direct benefits, which may include better movement, increased energy, decreased
fatigue, improved balance, and improved quality of your walking.

•

You will not be paid for your participation

•

You will be provided a copy of this consent form.

•

Taking part in this research project is voluntary. You don’t have to take part and you
can stop at any time.

INVITATION
You are invited to take part in this research study. The information in this form is meant to
help you decide whether or not to participate. If you have any questions, please ask.

Why are you being asked to be in this research study?
You are being asked to be in this study because you have a diagnosis of Parkinson’s
disease, you are able to walk (with or without a device) and you can stand to complete
the exercises, you have not been in an LSVT BIG exercise program in the past year, and
do not have a diagnosis of a past heart attack, stroke or other neurologic diagnosis, or
surgical procedure for treatment of PD such as a deep brain stimulator. You are 19 years
of age or older to participate.

What is the reason for doing this research study?
People with Parkinson’s disease can have a variety of motor symptoms such as tremors,
slowed movement, and decreased balance. These symptoms can lead to difficulty
moving and walking and increased falls. The focus of this research is to see if an exercise
program called LSVT BIG can help with these problems. Although LSVT BIG has been
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advertised a lot making it a well-known treatment for people with PD, it does not have a
lot of research to prove it works.
The main goal of this research is to see if LSVT BIG exercises help people move and walk
better.

What will be done during this research study?
You will receive evaluations immediately before treatment, immediately after treatment,
and four weeks after finishing the treatment. The treatment itself will take four weeks.
The total time of the study will take about 12 weeks. There are two parts to consider
when thinking about how much time it will take, the testing and the treatment.
Testing:
You will be given questions to complete at home that include topics such as confidence
with movement, depression, fatigue, and activity level as well as requests for your
medication and health history. This may take between 30 and 60 minutes in total to
finish.
You will then be seen in the physical therapy clinic for a series of tests that include
moving, walking, and balance. This may take between 1 ½ - 2 hours. Some of these tests
may be videotaped.
Treatment:
LSVT BIG is an exercise delivered 1:1 by trained LSVT BIG clinicians. Each treatment
session includes daily exercises similar to lunges and sidestepping, movements you
normally do every day such as getting up and down from a chair or in and out of bed, and
walking.
You will come to the physical therapy clinic for the LSVT BIG treatment intervention for 1
hour 4x a week x 4 weeks for a total of 16 hours. You will also perform the
exercise/treatment protocol a second time on those days as well as twice a day on nonclinic days.

How will my data be used?
All data collected will be stored and analyzed here at the University of Rhode Island by
staff associated with the study.

What are the possible risks of being in this research study?
There are minimal risks with participation in this study. Your risks, harms, or discomforts
should be no more than those felt when doing any regular exercise program. This may
include but not be limited to muscle strain or soreness, risk for falls, and risk for
cardiovascular event.
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What are the possible benefits to you?
You may have some direct benefits from the participating in the therapy, which may include
improved mobility, increased energy, decreased fatigue, improved balance, and improved
quality of your walking.

What are the possible benefits to other people?
If the results of this study show good improvement in moving and walking it would
support LSVT BIG as a treatment choice for PwPD. This could help clinicians try and get
more trained therapists in the exercise as well as support insurance payment for such
programs

What are the alternatives to being in this research study?
Instead of being in this research study you can contact a local physical therapy clinic that
offers the LSVT BIG program or any physical therapy for people with PD. This lets you get
the treatment without any additional time needed to do the research testing.

What will being in this research study cost you?
There is no cost to you to be in this research study.

Will you be compensated for being in this research study?
You will not receive any compensation for participating in this research study.

What should you do if you have a problem during this research study?
If you have a problem or experience harm as a direct result of being in this study, you
should immediately contact one of the people listed at the beginning of this consent
form. If needed, seek immediate emergency care for this problem. Please note, it is the
policy of URI not to pay for any required care. Agreeing to this does not mean you have
given up any of your legal rights.

How will information about you be protected?
Steps will be taken to protect your privacy and the confidentiality of your study data.
Your part in this study is confidential. HIPPA will be followed for all protected health
information (PHI) collected. A participant medical record (paper) will be made and
stored onsite in a locked location in the URI Physical Therapy Department. All electronic
data related to wearable technology will be uploaded to a secure online
platform/website made for research. All data entered into computers for analysis
purposes will be de-identified (cannot identify who the information belongs to) and
files and computers will be password protected.
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The data will be stored in a locked cabinet in the researcher’s office and will only be seen
by the research team during the study and for 5 years after the study is complete.
The only persons who will have access to your research records are the study personnel,
the Institutional Review Board (IRB), and any other person, agency, or sponsor as
required by law. The information from this study may be published in scientific journals
or presented at scientific meetings but the data will be reported as group or summarized
data and your identity will be kept strictly confidential.

What are your rights as a research subject?
You may ask any questions concerning this research and have those questions answered
before agreeing to participate in or during the study.
For study related questions, please contact the investigator(s) listed at the beginning of this
form.
For questions concerning your rights or complaints about the research contact the
Institutional Review Board (IRB) or Vice President for Research and Economic Development:
•
•

IRB: (401) 874-4328 / researchintegrity@etal.uri.edu.
Vice President for Research and Economic Development: at (401) 874-4576

What will happen if you decide not to be in this research study or decide to stop
participating once you start?
You can decide not to be in this research study, or you can stop being in this research
study (“withdraw’) at any time before, during, or after the research begins for any
reason. Deciding not to be in this research study or deciding to withdraw will not affect
your relationship with the investigator or with the University of Rhode Island (list others
as applicable). You will be provided with a list of resources regarding local therapy clinics
that provide LSVT BIG and treatment alternatives.
You will not lose any benefits to which you are entitled.
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Documentation of informed consent
You are voluntarily making a decision whether or not to be in this research study. Signing this
form means that
(1) you have read and understood this consent form,
(2) you have had the consent form explained to you,
(3) you have had your questions answered and
(4) you have decided to be in the research study. You will be given a copy of this consent
form to keep.
Participant Name:
______________________________________
(Name of Participant: Please print)
Participant Signature:
______________________________________
Signature of Research Participant

_______________
Date

Investigator certification:
My signature certifies that all elements of informed consent described on this consent
form have been explained fully to the subject. In my judgment, the participant possesses
the capacity to give informed consent to participate in this research and is voluntarily
and knowingly giving informed consent to participate.

Date

______________________________________
Signature of Person Obtaining Consent

105

_______________

AUDIO/VIDEO ADDENDUM TO THE CONSENT FORM FOR RESEARCH
By signing this consent form, I confirm that I give my permission for photo and video
recording(s) of me, to be used for the purposes listed above, and to be retained
indefinitely. You may still participate in this study if you are not willing to be recorded.
___________________________________
Printed Name of Participant
___________________________________
Signature of Participant

______________________
Date

___________________________________
Printed Name of Person Obtaining Consent
___________________________________
Signature of Person Obtaining Consent

______________________
Date
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ADDENDUM FOR HIPAA INFORMATION (PERSONAL HEALTH INFORMATION) ACCESS
You have rights regarding the privacy of your medical information collected before and
during this research. This medical information, called “protected health information” (PHI),
typically may include, depending upon the nature of this research, demographic information
(like your address and birth date), the results of physical exams, blood tests, x-rays and other
diagnostic and medical procedures, as well as your medical history.
By signing this consent form, you are allowing the research team to have access to your PHI.
The research team includes the investigators listed on this consent form and other personnel
involved in this specific study at [add additional personnel/institutions as applicable].
Your PHI will be used only for the purpose(s) described in the section “What is the reason for
doing this research study?”
Your PHI will be shared, as necessary, with the Institutional Review Board (IRB) and with any
person or agency required by law. You are also allowing the research team to share your PHI
with other people or groups listed below all of these persons or groups listed below are
obligated to protect your PHI.
You may cancel your authorization for further collection of PHI for use in this research at any
time by contacting the principal investigator in writing. However, the PHI which is not
included in the research data obtained to date may still be used. If you cancel this
authorization, you will no longer be able to participate in this research.
•

Researchers at University of Rhode Island involved in this study

You are authorizing us to use and disclose your PHI for as long as the research study is being
conducted.
___________________________________
Printed Name of Participant
___________________________________
Signature of Participant

______________________
Date

___________________________________
Printed Name of Person Obtaining Consent
___________________________________
Signature of Person Obtaining Consent

______________________
Date
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APPENDIX C

Consent Form for Research – Addendum for Blood Draw
STUDY TITLE
LSVT BIG Exercise-Induced Neuroplasticity in People with Parkinson’s Disease: An Assessment
of Physiological and Behavioral Outcomes – Blood Draws
PRINCIPAL INVESTIGATORS
Leslie Mahler, PhD, CCC-SLP
lmahler@uri.edu
Christine Clarkin, DPT
chrisclarkin@uri.edu

Phone: 401-874-2490

Email:

Phone: 401-662-5367

Email:

KEY INFORMATION
•

You have chosen to participate in the LSVT BIG Exercise Study and the FULL consent
form regarding the study has been reviewed with you already and you have a copy
of that consent form.

•

This consent form contains information only related to the blood draws

What will be done during this research study? – BLOOD DRAWS
You will be seen in the Kinesiology phlebotomy lab, located at 25 West Independence
Way, for a blood draw on three separate occasions during the study (initial, immediately
following treatment, and 4 weeks later) over the course of the 12-week study). The lab
technician will draw blood by putting a needle into the vein of your arm. Two small
tubes of blood will be taken (approximately 2 teaspoons). The needle stick may hurt. You
will then be offered a small snack (e.g. granola bar) and drink (water, juice) when the
blood draw is complete.
What are the possible risks of being in this research study? – BLOOD DRAWS
There are minimal risks associated with participation with the blood draw. There is a
small risk of bruising, bleeding, fainting, and a rare risk of infection. You will be offered a
snack and monitored as indicated.
How will information about you be protected? – BLOOD DRAWS
Your blood samples will have a nonidentifying study code and number to protect your
privacy. They will be stored in a freezer in a secured Kinesiology lab at Independence
Square until analysis. The samples may be stored and used for analysis for up to 5 years
and will then be disposed of according to University policy.
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Documentation of informed consent
You are voluntarily making a decision whether or not to be in this research study. Signing this
form means that
(1) you have read and understood this consent form
(2) you have had the consent form explained to you,
(3) you have had your questions answered and
(4) Initial next to your choice and sign below.
__________YES - you have decided to allow your blood to be drawn as a part of the LSVT
BIG study. You will be given a copy of this consent form to keep.
__________NO – you have decided NOT to allow your blood to be drawn as part of the
LSVT BIG study. You will be given a copy of this consent form to keep as part of your other
participation forms.

Participant Name:
______________________________________
(Name of Participant: Please print)
Participant Signature:
______________________________________
Signature of Research Participant

_______________
Date

Investigator certification:
My signature certifies that all elements of informed consent described on this consent
form have been explained fully to the subject. In my judgment, the participant possesses
the capacity to give informed consent to participate in this research and is voluntarily
and knowingly giving informed consent to participate.
______________________________________
Signature of Person Obtaining Consent
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_______________
Date

APPENDIX D
LSVT BIG Summary Protocol
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APPENDIX E
World Health Organization
International Classification of Function, Disability and Health
The World Health Organization outlined the ICF in 2000 to integrate a more
comprehensive perspective of disability, complement research outcome measures, and
provide consistent, comparable, and universal guidance between researchers as well as
on an international level The ICF interactive model identifies three levels of human
functioning: functioning at the level of body or body part, the whole person, and the
whole person in his or her complete environment. These levels in turn define three
functional dimensions: body functions and structures, activities, and participation that
can be addressed with specific measures (World Health Organization 2000).
ICF Level 1: Participation
Participation is involvement in a life situation. Participation restrictions are problems
an individual may experience in involvement in life situations (Bickenbach, Chatterji,
Kostanjsek, and Ustun 2003).
ICF Level 2: Activity
Activity is the execution of a task or action by an individual. Activity limitations are
difficulties an individual may have in executing activities (Bickenbach et al., 2003).
ICF Level 3: Body Structure and Function
Body functions are physiological functions of body systems including psychological
functions. Body structures are anatomical parts of the body such as organs, limbs and
their components. Impairments are problems in body function or structure such as a
significant deviation or loss (Bickenbach et al. 2003).
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APPENDIX F
Comprehensive List of Outcome Measures
Activities Specific Balance Confidence Scale (ABC) is a subjective self-reported
measure of confidence in performing various ambulatory activities without falling or
experiencing a sense of unsteadiness. It is a 16-item questionnaire with a 0-1600 score
divided by 100 and reported as a percentage. It has a high level of internal consistency
(Powell and Meyers 1995; Steffen and Seney 2008).
Cumulative Illness Rating Scale for Geriatrics (CIRS-G) is an interview-based
instrument to measure medical comorbidity in relationship to disability and has been
validated as an effective measure in PwPD (Visser et al., 2004).
Functional Gait Assessment (FGA) is a 10-item test with each item scored 0-3 with
a total score of 30. The higher the score the higher the functional performance. It takes
5-10 minutes to administer (Weber et al., 2016).
Gait Analysis will be measured with wearable technology and include stride length,
lower and upper limber speed, and over all gait speed.
Gait Speed (10-Meter walk) is the measure of time it takes to complete a 10-meter
walk with the patient’s preferred device. Gait speed, turning speed, and stride length
have been found to be highly correlated to severity of disease and patient perception of
mobility disability (Curtze et al., 2016).
Geriatric Depression Scale (GDS – 30) is a short, self-report, yes/no screening
instrument for depression in the elderly (Yesavage et al., 1982). The GDS is short and
easily understood, making it appropriate for use in both clinical research and routine
clinical care as a screening instrument for depression in elderly PD patients (Schrag et
al., 2007). It focuses on the psychological aspects and social consequences of
depression, avoiding symptom overlap with medical disorders, such as PD, or aging in
general. Each question on the GDS-30 can only be scored “0” or “1,” for a total score
of 30 with the higher score indicating higher severity of depression (normal 0-9; mild
depressive 10-19; severe depressive 20-30). The instrument is not able to capture
degrees of severity at the level of individual items, however, there is preliminary
evidence that the overall scale may be sensitive to changes in depression severity
(Schrag et al., 2007).
Hoehn & Yahr Staging (H&Y) - is a 5 point scale that describes the stage of disease
from a clinical perspective from 0 – Asymptomatic, 1 – Unilateral involvement only, 2
– Bilateral involvement without impairment of balance, 3 – Mild to moderate
involvement; some posture instability but physically independent; Needs assistance to
recover from the pull test, 4 – Severe disability; still able to walk or stand unassisted,
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and 5 – Wheelchair bound or bed ridden unless aided (Goetz et al., 2004). This is
included in the MDS-UPDRS.
Mini-Balance Evaluation System Test (Mini BESTest) is a valid and reliable
clinical balance scale to assess falls risk and postural control in people with PD
(Duncan and Leddy 2013). It is a unidimensional test modified from the original 36
item BESTest ( and different from the Brief-BESTest a 6-item test across all domains
of the original test) and focuses specifically on dynamic balance (Bravini et al., 2016).
It consists of 14 items with each task scored on a 3-point ordinal scale (0-2 rating)
with a maximum score of 28 and a higher score indicating better performance
(Franchignoni et al., 2010; Schlenstedt et al., 2015). It takes 10-15 minutes to
administer and includes the TUG.
The Montreal Cognitive Assessment (MoCA) is a one-page 30-point test
administered in 10 minutes intended to serve as a screen tool for cognitive impairment
in a variety of patient populations covering 8 cognitive domains including
visuospatial/executive functioning (5 points), memory and delayed recall (5 points),
attention, concentration, and working memory (6 points), language and naming (6
points), abstraction (2 points), and orientation (6 points) (Brown et al., 2016). Initial
analyses indicated that persons with 12 years of education or less tended to have worse
performance on the MoCA therefore to correct for education effects 1 point is added
for participants with 12 years of education or less on their total MoCA score (if <30)
(Zadikoff et al., 2008). The recommended total cutoff score to detect mild cognitive
impairment for people with PD (PD-MCI) is <26 with the specificity of the MoCA to
exclude elderly normal controls good (87%) and sensitivity in detecting MCI excellent
(90%) compared to the MMSE (18%) (Brown et al., 2016; Zadikoff et al., 2008).
(The Movement Disorder Society (MDS) Task Force for creating diagnostic
procedures PwPD for dementia initially recommended the Mini-Mental State Exam
(MMSE) as the most appropriate standard objective assessment of global cognitive
functioning but they revised their criteria in 2012 replacing the MMSE with the
MoCA (Brown et al., 2016). The measure desired in the study or clinical application,
baseline status versus change over time, must be taken into consideration however, as
a study released around the same time found that while the MoCA may be more
sensitive to cognitive change at baseline than the MMSE, the MoCA did not appear to
change over time while the MMSE did (Lessig et al., 2012). This study is utilizing the
measure for baseline status only therefore the MoCA will be utilized. )
Movement Disorder Society Unified Parkinson’s Disease Rating (MDS-UDRS) Unified Parkinson’s Disease Rating Scale (UPDRS) which was originally developed
in the 1980s and became the most widely used clinical rating scale for PD, was revised
and termed the MDS sponsored UPDRS revision (MDS-UPDRS) and is used as the
primary international rating scale for PD clinical care and research (Goetz et al.,
2008). The MDS-UPDRS has four parts, namely, I: Non-motor Experiences of Daily
Living (13 items); II: Motor Experiences of Daily Living (13 items); III: Motor
Examination (18 items); IV: Motor Complications (6 items). There is a 5-point range
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for each item - normal (0), slight (1), mild (2), moderate (3), and severe (4) with a
higher score indicating higher disability. Factor structure of the new scale has been
determined to be both clinimetrically sound and clinically pertinent but is has been
recommended that each of the four parts (I-IV) be reported separately and not
collapsed into a single “total MDS-UPDRS” summary score (Goetz et al., 2008).
MDS-UPDRS Part I: Non-motor Experiences of Daily Living
Part I has two components: IA concerns a number of behaviors that are assessed by the
investigator with all pertinent information from patients and caregivers, and IB is
completed by the patient with or without the aid of the caregiver, but independently of
the investigator. These sections can, however, be reviewed by the rater to ensure that
all questions are answered clearly, and the rater can help explain any perceived
ambiguities. It is comprised of 13 items with a 0-4 rating for a range from 0 to 52 with
a higher score indicating higher level of severity and disability. It requires a 5-10
minutes to complete (Goetz et al., 2008).
MDS-UPDRS Part II: Motor Experiences of Daily Living is a self-administered
survey of 13 items with a 0-4 rating for a range from 0 to 52 with a higher score
indicating a higher level of severity and disability. It requires 5-10 minutes to
complete.
MDS-UPDRS Part III: Motor Examination
Part III has instructions for the rater to give or demonstrate to the patient; it is
completed by the rater. It is comprised of 18 items with a 0-4 rating for a range from 0
to 72 with a higher score indicating higher level of severity and disability. It requires
20-30 minutes to complete. It also includes a question regarding medication, ON/OFF
state at time of exam, and a final Hoehn and Yahr stage rating (Goetz et al., 2008).
MDS-UPDRS Part IV: Motor Complications
Part IV has instructions for the rater and also instructions to be read to the patient. This
part integrates patient-derived information with the rater’s clinical observations and
judgments and is completed by the rater. It is comprised of 6 items with a 0-4 rating
for a range from 0 to 24 with a higher score indicating higher level of severity and
disability from dyskinesias. It requires 5-10 minutes to complete (Goetz et al., 2008).
Parkinson’s Disease Questionnaire-39 – Quality of Life measure (PDQ-39) is a
self-report quality of life (QoL) questionnaire used to assess health-related QoL in
individuals with PD. The instrument assesses QoL across 8 domains: mobility,
activities of daily living, emotional well-being, stigma, social support, cognitive
impairment, communication, and bodily discomfort. It takes 10-20 minutes to
administer, provides a score from 0-100 with lower scores indicating better QoL, has
excellent test-retest reliability, excellent internal consistency, and minimal detectable
change (MDC) for each dimension identified (Hagell 2003; Hagell 2007).
Parkinson's Disease Fatigue Scale (PFS-16) is a patient-rated scale that measures
fatigue, one of the non-motor symptoms associated with Parkinson's. The scale allows
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the measurement of the presence of fatigue (seven items) and also its impact on daily
function (nine items) and takes around five minutes to administer. It can be used to
assess levels of fatigue and measure any changes that treatment or lifestyle changes
may effect. The PFS-16 is available for download by healthcare professionals or notfor-profit researchers (richard.g.brown@kcl.ac.uk) to request permission for use.
(Brown, Dittner, Findley, & Wessely 2005).
Physical Activity and Disability Survey (PADS-R) is a measure of physical activity
in people with neurologic conditions that takes 15-20 minutes to administer (Kayes et
al., 2009).
Timed Up and Go (TUG) assesses mobility, balance, walking ability, and falls risk in
older adults, has good inter and intra-rater reliability, and is useful for following
clinical change over time as well as predict safety with gait (Podsiadlo and Richardson
1991).
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APPENDIX G

LSVT BIG 2019 Study – Participant Survey
Since participating in the BIG
Program……….
I am moving better in my day to day
activities
I am more confident with my day to day
activities
Friends and family have noticed I am
moving better since participating in this
program
I have less fatigue
I am sleeping better
I am more likely to participate in social
activities
I am likely to continue with some type of
exercise after finishing the BIG program
I am likely to share
information/recommend the program to
others with Parkinson’s disease
The Fitbit gave me helpful information
about my activity and steps
I am likely to continue to use the Fitbit
as an activity monitor

Strongly Disagree Neutral Agree
Disagree
1
2
3
4

Strongly
Agree
5

1

2

3

4

5

1

2

3

4

5

1
1
1

2
2
2

3
3
3

4
4
4

5
5
5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

Rank in order of benefit (to you) the different components of the BIG program
(1 = most important; 7= least important)
Please choose each number only once

The intensity of the program (high effort)
One on one coaching and feedback
The frequency of the program (attending 4x a
week)
The frequency of the exercises (performing 2x
a day)
The daily exercises which were challenging
The daily components which were functional
The hierarchy activities which were practical

1
1
1

2
2
2

3
3
3

4
4
4

5
5
5

6
6
6

7
7
7

1

2

3

4

5

6

7

1
1
1

2
2
2

3
3
3

4
4
4

5
5
5

6
6
6

7
7
7

The most beneficial part of the BIG program was:
The least beneficial part of the BIG program was:
What I liked most about the BIG program was:
What was most challenging about the BIG program was:
I think the program could be better if:
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